Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Numb er: 20200362  
Protocol Version 1.0, 09 February 2021  Page 1 of 67 TITLE PAGE  
Protocol  
An Open -label Single -dose Study to Evaluate the Pharmacokinetics  of 
Sotorasib in Healthy Subjects and Subjects with Moderate or Severe Hepatic 
Impairmen t  
Protocol Status: Final  
Protocol Date: 09 February 2021  
Protocol Version: 1.0  
Investigational Product: Sotorasib (AMG 510)  
Amgen Protocol Reference Number: 20200362  
Covance Study Number: 8454975  
Sponsor:  
Amgen, Inc.  
One Amgen Center Drive  
Thousand Oaks, Califor nia 91320  
USA  
Study ID: [REMOVED]
This NCT number has been applied to the document for
purposes of posting on Clinicaltrials.gov
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Numb er: 20200362  
Protocol Version 1.0, 09 February 2021   Page 2 of 67 Confidentiality Notice  
This document contains confidential information of Amgen Inc.  
This document must not be disclosed to anyone other than the site study staff and 
members of the Institutional Review Board/Independent Ethics Committee/Institutional 
Scientific Review Board or equivalent.  
The information in this document cannot be used for any purpose other than the 
evaluation or conduct of the clinical investigation without the prior written consent of 
Amgen Inc.  
If you have questions regarding how this document may be used or shared, call the 
Amgen Medical Information number: US sites, 1 - 800-77-AMGEN; Canadian sites, 
1-866-50-AMGEN; Amgen’s general number in the US, 1 -805-447-1000.  
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Numb er: 20200362  
Protocol Version 1.0, 09 February 2021   Page 3 of 67 INVESTIGATOR AGREEMENT  
I have read the pro tocol entitled “An Open -label Single -dose Study to Evaluate the 
Pharmacokinetics of Sotorasib in Subjects with Moderate and Severe Hepatic Impairment 
Compared to Healthy Subjects” and agree to conduct the study as described herein.  
I agree to comply with t he International Council for Harmonisation (ICH) Tripartite Guideline 
on Good Clinical Practice (GCP), Declaration of Helsinki, and applicable national or regional 
regulations/guidelines.  
I agree to ensure that the confidential information contained in this document will not be used for 
any purpose other than the evaluation or conduct of the clinical investigation without the prior 
written consent of Amgen Inc.  
 
 
_______________________________________         
Signature  
 
__________________________________ _____        
Name of Investigator        Date (DD Month YYYY)  
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Numb er: 20200362  
Protocol Version 1.0, 09 February 2021   Page 4 of 67 STUDY IDENTIFICATION  
Sponsor  Amgen Inc.  
One Amgen Center Drive  
Thousand Oaks, California 91320  
USA  
Sponsor’s Study Contact  , PhD  
Clinical Pharmacologist  
Amgen Inc.  
One Amgen Center Drive  
Thousand Oaks, California 91320  
USA  
Tel: 
Email:  
Medical Monitor  
 , MD, PhD  
Medical Director  
Covance Clinical Pharmacology Services  
3301 Kinsman Boulevard  
Madison, Wisconsin 53704  
USA  
Tel (Office)
Email:  
Covance Project Manager   
Project Manager  
Covance Clinical Pharmacology Services  
3301 Kinsman Boulevard  
Madison, Wisconsin 53704  
USA  
Tel:
Email:  
Sponsor’s Study Manager   
Global Early Clinical Development Manager  
Amgen Inc.  
One Amgen Center Drive,  
Thousand Oaks, California 91320  
USA  
Tel:
Email:  
Statistician  , MS  
Senior Biostatistician  
Covance, Inc.  

Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Numb er: 20200362  
Protocol Version 1.0, 09 February 2021   Page 5 of 67 3301 Kinsman Boulevard  
Madison, Wisconsin 53704  
USA  
Tel:
Email:  

Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Numb er: 20200362  
Protocol Version 1.0, 09 February 2021   Page 6 of 67 SYNOPSIS  
Title of study: An Open -label Single -dose Study to Evaluate the Pharmacokinetics of 
Sotorasib in Subjects with Moderate or Severe  Hepatic Impairment Compared to Healthy 
Subjects  
Objectives:  
The primary objective of the study is:  
 to evaluate the pharmacokinetics (PK) of a single oral dose of sotorasib administered 
in subjects with moderate or severe hepatic impairment compared to subjects with 
normal hepatic function.  
The secondary objective of the study is:  
 to evaluate the safety and tolerability of sotorasib administered in subjects with 
moderate or severe hepatic impairment compared to subjects with normal hepatic 
function.  
Study design:  
This will be a Phase 1, parallel -arm, multi -center (US), open -label, non -randomized study to 
evaluate the PK of a single oral dose of sotorasib administered in subjects with normal hepatic 
function (control) and in subjects with moderate or sev ere hepatic impairment (according to 
Child -Pugh classification) under fasted conditions. Subjects who meet eligibility requirements 
will be assigned to 1 of 3 groups as shown below:  
Group  Degree of Hepatic Impairment  Number of Subjects  
1 Normal function (no impairment)  6 to 8 
2 Moderate impairment (Child -Pugh Class B)  6 to 8  
3 Severe impairment (Child -Pugh Class C)  6 to 8  
The classification is based on Child -Pugh scores as per Figg and Dukes.  
 Attempts will be made to match for age (mean  10 years), sex, and body mass index (mean  
20) of the healthy subjects to the combined moderate and severe impairment subjects.   
Up to 8 subjects can be enrolled in Group 1 to satisfy matching criteria. Up to 8 subjects will 
be enrolled in Groups 2 and 3 to ensure 6 evaluable subjects. Subjects will maintain the same 
group assignment throughout the study.  
Potential subjects will be screened to assess their eligibility to enter the study within 28  days 
prior to the dose administration. Subjects will be ad mitted into the study site on Day  1 and be 
confined until discharge on Day  8. On Day 1, after at least a 10 -hour fast, all subjects will 
receive a single oral dose of 960 mg sotorasib (8 x 120-mg tablets).  
Number of subjects:  
Approximately up to 2 4 subjects will be enrolled, with a minimum of 6 evaluable subjects and 
a maximum of up to 8 subjects in Group 1, and a maximum of 16 subjects enrolled in Groups 2 
and 3 (8 subjects in each hepatic impairment group to ensure 6 evaluable subjects).  
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Numb er: 20200362  
Protocol Version 1.0, 09 February 2021   Page 7 of 67 Diagnosi s and main criteria for inclusion:  
Male subjects or female subjects, aged between 18 and 70 years (inclusive); with a body mass 
index between 18.0 and 38.0 kg/m2 (inclusive); with normal hepatic function, moderate hepatic 
impairment, or severe hepatic impa irment. Female subjects will be of nonchildbearing 
potential.  
Investigational products, dose, and mode of administration:  
960 mg sotorasib, given orally as 8 x 120-mg tablets, on Day 1 following at least a 10 -hour 
fast.  
Duration of subject participation in the study:  
The total duration of study participation for each subject (from Screening through end of 
study) is anticipated to be approximately 4 weeks.  
Primary Endpoints:  
The primary endpoints of the study are PK parameters for sotorasib : 
 maximum observed plasma concentration (C max) 
 area under the plasma concentration ‑time curve (AUC) from time zero to the last 
quantifiable concentration (AUC last) 
 AUC from time zero to infinity (AUC inf). 
 
Additional PK parameters may be calculated.  
 
Secondary Endpoints:  
The secondary endpoints of the study are:  
 adverse events  
 clinical laboratory evaluations  
 12-lead electrocardiograms  
 vital signs  
 unbound C max (Cmax,u) 
 unbound AUC last (AUC last,u) 
 unbound AUC inf (AUC inf,u) 
 unbound apparent total plasma c learance (CL u/F) 
 unbound apparent volume of distribution during the terminal phase (V z,u/F). 
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Numb er: 20200362  
Protocol Version 1.0, 09 February 2021   Page 8 of 67 Statistical methods:  
The primary PK parameters are C max, AUC last, and AUC inf for sotorasib. Other PK parameters 
for sotorasib may include time of maximum observed concentration (t max), apparent plasma 
terminal elimination half -life (t 1/2,z), apparent total plasma clearance (CL/F), apparent volume 
of distribution during the terminal elimination phase (V z/F), unbound fraction (f u), C max,u, 
AUC last,u, AUC inf,u, CL u/F, and V z,u/F. A linear model will be used to analyze log -transformed 
primary PK parameters. The data from hepatically impaired subjects (Group 2 and 3; tests) and 
control subjects (normal hepatic function [Group 1]; reference) will be included in the analysis. 
Geometric mean ratios (Test/Reference) for C max and AUC values and associated 90  
confidence intervals will be estimated.  
Additional parameters may be calculat ed, and sotorasib metabolites may be analyzed.  Specific 
details will be presented in the Statistical Analysis Plan for this study.  
Safety analysis:  
The number and percentage of subjects reporting any treatment -emergent adverse events will 
be tabulated by Medical Dictionary for Regulatory Activities system organ class and preferred 
term. Tables of fatal adverse events, serious adverse events, adverse events leading to 
withdrawal from investigational product or other protocol -required therapies, and signific ant 
treatment -emergent adverse events will also be provided. Subject -level data may be provided 
instead of tables if the subject incidence is low.  
Observed values for clinical laboratory data, 12 -lead electrocardiograms, and vital signs will 
be summarized . There will be no formal statistical analysis for safety.  
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Numb er: 20200362  
Protocol Version 1.0, 09 February 2021   Page 9 of 67 TABLE OF CONTENTS  
TITLE PAGE  ................................ ................................ ................................ ............................. 1 
INVESTIGATOR AGREEME NT................................ ................................ ............................. 3 
STUDY IDENTIFICATION  ................................ ................................ ................................ .....4 
SYNOPSIS  ................................ ................................ ................................ ................................ .6 
TABLE OF CONTENTS  ................................ ................................ ................................ ........... 9 
LIST OF TABLES AND F IGURES ................................ ................................ ........................ 12 
LIST OF ABBREVIATION S ................................ ................................ ................................ ..13 
1. INTRODUCTION  ................................ ................................ ................................ ........... 15 
1.1. Background  ................................ ................................ ................................ ............ 15 
1.2. Pharmacokinetics  ................................ ................................ ................................ ...16 
1.3. Study Rationale  ................................ ................................ ................................ ......17 
1.4. Benefit -risk Assessment ................................ ................................ ......................... 17 
1.4.1.  Therapeutic Context  ................................ ................................ ..................... 17 
1.4.1.1.  Key Benefits ................................ ................................ ....................... 17 
1.4.1.2.  Risks  ................................ ................................ ................................ ...17 
2. OBJECTIVES AND ENDPO INTS  ................................ ................................ ................. 19 
2.1. Objectives  ................................ ................................ ................................ .............. 19 
2.2. Endpoints  ................................ ................................ ................................ ............... 20 
2.2.1.  Primary Endpoints  ................................ ................................ ....................... 20 
2.2.2.  Secondary Endpoints  ................................ ................................ ................... 20 
3. INVESTIGATIONAL PLAN  ................................ ................................ .......................... 20 
3.1. Overall Study Design and Plan  ................................ ................................ .............. 20 
3.2. Discussion of Study Design  ................................ ................................ ................... 22 
3.3. Selection of Doses in the Study  ................................ ................................ ............. 22 
4. SELECTION OF STUDY P OPULATION  ................................ ................................ .....23 
4.1. Inclusion Criteria  ................................ ................................ ................................ ...23 
4.2. Exclusion Criteria  ................................ ................................ ................................ ..24 
4.3. Screen Failures and Rescreening  ................................ ................................ ........... 27 
4.4. Subject Number and Identification  ................................ ................................ ........ 27 
4.5. Subject Withdrawal and Replacement  ................................ ................................ ...27 
4.6. Study Termination  ................................ ................................ ................................ .28 
5. STUDY TREATMENTS  ................................ ................................ ................................ .28 
5.1. Investigational Product  ................................ ................................ .......................... 28 
5.2. Treatment of Overdose  ................................ ................................ .......................... 29 
5.2.1.  Medical Devices ................................ ................................ ........................... 29 
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Numb er: 20200362  
Protocol Version 1.0, 09 February 2021   Page 10 of 67 5.2.2.  Product Complaints  ................................ ................................ ...................... 30 
5.3. Randomization  ................................ ................................ ................................ .......30 
5.4. Blinding ................................ ................................ ................................ .................. 30 
5.5. Treatment Compliance  ................................ ................................ ........................... 30 
5.6. Drug Accountability ................................ ................................ ............................... 30 
6. CONCOMITANT THERAPIE S AND OTHER RESTRICT IONS  ................................ 31 
6.1. Concomitant Therapies  ................................ ................................ .......................... 31 
6.2. Diet ................................ ................................ ................................ ......................... 31 
6.3. Smoking  ................................ ................................ ................................ ................. 32 
6.4. Exercise  ................................ ................................ ................................ .................. 32 
6.5. Blood Donation  ................................ ................................ ................................ ......32 
7. STUDY ASSESSMENTS AN D PROCEDURES  ................................ ........................... 32 
7.1. Pharmacokinetic Assessments  ................................ ................................ ............... 33 
7.1.1.  Pharmacokinetic Blood Sample Collection a nd Processing  ........................ 33 
7.1.2.  Analytical Methodology  ................................ ................................ .............. 33 
7.2. Safety and Tolerability Assessments  ................................ ................................ .....33 
7.2.1.  Adverse Events and Serious Adverse Events: Time Period and Frequency 
for Collecting and Reporting Safety Event Information  .............................. 33 
7.2.2.  Clinical Laboratory Evaluations  ................................ ................................ ..36 
7.2.3.  Vital Signs  ................................ ................................ ................................ ....36 
7.2.4.  12-lead Electrocardiogram  ................................ ................................ ........... 37 
7.2.5.  Physical Examination ................................ ................................ ................... 37 
8. SAMPLE SIZE AND DATA  ANALYSIS  ................................ ................................ ......37 
8.1. Determination of Sample Size  ................................ ................................ ............... 37 
8.2. Analysis Populations  ................................ ................................ .............................. 37 
8.2.1.  Pharmacokinetic Population  ................................ ................................ ........ 37 
8.2.2.  Safety Population  ................................ ................................ ......................... 38 
8.3. Pharmacokinetic Analyses  ................................ ................................ ..................... 38 
8.4. Safety Analysis  ................................ ................................ ................................ ......38 
9. REFERENCES  ................................ ................................ ................................ ................ 38 
10. APPENDICES  ................................ ................................ ................................ ................. 40 
Appendix 1: Safety Events: Definitions and Procedures for Recording, Evaluating, 
Follow -up, and Reporting of Adverse Event  ................................ ......................... 41 
Appendix 2: Clinical Laboratory Evaluations  ................................ ................................ ...49 
Appendix 3: Child -Pugh Classification of Severity of Cirrhosis ................................ .......50 
Appendix 4: Contraception Requirements  ................................ ................................ ......... 51 
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Numb er: 20200362  
Protocol Version 1.0, 09 February 2021   Page 11 of 67 Appendix 5: Collection of Pregnancy and Lactation Information  ................................ .....53 
Appendix 6: Regulatory, Ethical, and Study Oversight Considerations  ............................ 57 
Appendix 7: Hepatotoxicity: Suggested Actions and Follow -up Assessments  ................. 62 
Appendix  8: Schedule of Assessments  ................................ ................................ .............. 65 
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Numb er: 20200362  
Protocol Version 1.0, 09 February 2021   Page 12 of 67 LIST OF TABLES AND FIGURES  
Table 1:  Classification of Hepatic Impairment Groups  ................................ ........... 21 
Table  2: Investigational Pro duct(s)  ................................ ................................ .......... 29 
 
Figure  1: Study Schematic ................................ ................................ ......................... 22 
Figure 2:  Sample Serious Adverse Event Report Form  ................................ ............ 46 
Figure 3:  Pregnancy Notification Form  ................................ ................................ .....55 
Figure 4:  Lactation Notification Form  ................................ ................................ ......56 
 
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Numb er: 20200362  
Protocol Version 1.0, 09 February 2021   Page 13 of 67 LIST OF ABBREVIATIONS  
Abbreviation  Definition  
ALT  alanine aminotransferase  
AST  aspartate aminotransferase  
AUC  area under the plasma concentration -time curve  
AUC inf area under the plasma concentration -time curve from time zero to 
infinity  
AUC inf,u unbound area under the plasma concentration -time curve from time 
zero to infinity  
AUC last area under the plasma concentration -time curve from time zero to time 
of last quantifiable concentration  
CFR  Code of Federal Regulations  
CL u/F unbound apparent total plasma clearance  
Cmax maximum observed plasma concentration  
Cmax,u unbound maximum observed plasma concentration  
CYP  cytochrome P450  
DILI  drug-induced liver injury  
ECG  electrocardiogram  
eCRF  electronic Case Report Form  
EDC  electronic data capture  
EOS  end of study  
FDA  Food and Drug Administration  
FSH Follicle -stimulating hormone  
GCP  Good Clinical Practice  
IB Investigator’s Brochure  
ICF Informed Consent Form  
ICH International Council for/Conference on Harmonisation  
IMP investigational medicinal product  
INR international normalized ratio  
IRB Institutional Review Board  
KRAS  Kirsten rat sarcoma viral oncogene homolog  
P-gp P-glycoprotein  
PK pharmacokinetic(s)  
PPI proton -pump inhibitor  
QD once daily  
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Numb er: 20200362  
Protocol Version 1.0, 09 February 2021   Page 14 of 67 QTcF  QT interval corrected for heart rate using Fridericia’s method  
RBC  red blood cell  
t1/2,z apparent plasma terminal elimination half -life 
TBL  total bilirubin  
tmax time of the maximum observed plasma concentration  
ULN  upper limit of normal  
Vz,u/F unbound apparent volume of distribution during the terminal phase  
WBC  white blood cell  
 
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Numb er: 20200362  
Protocol Version 1.0, 09 February 2021   Page 15 of 67 1. INTRODUCTION  
Refer to the Investigator’s Brochure (IB)1 for detailed information concerning the available 
pharmacology, toxicology, drug metabolism, clinical studies, and adverse event profile of the 
investigational medicinal product (IMP).  
1.1. Backgro und 
Investigational Medicinal Product  
The role of Kirsten rat sarcoma viral oncogene homolog ( KRAS ) gene mutations in human 
cancers has been known for decades;2 however, no anticancer therapies targeting KRAS  
mutations have been successfully developed. Thus, an unmet need exists for therapies that can 
specifically target cancers driven by KRAS  mutations. Sotorasib is one  such small molecule that 
specif ically and irreversibly inhibits the protein product of a mutant KRAS  gene, which results in 
a G12C mutation at the protein level ( KRAS  p.G12C ). One mutant version of KRAS , KRAS 
p.G12C , which encodes the KRASG12C protein, might be tractable for small molecule inhibition 
through a covalent interaction with the mutant cysteine3,4,5 found in approximately 13  of lung 
adenocarcinoma (nonsquamous, non -smal l---cell lung carcinoma), 3  of colorectal cancer, and 
1 to 2 of numerous other solid tumors.6,7,8 Sotorasib forms a specific covalent bond with the 
mutant cysteine of KRASG12C, irreversibly locking the protein in an inactive conformation that 
cripples oncogenic signaling.5 As inactivation of KRAS  has been demonstrated to inhibit cell 
grow th and/or promote apoptosis selectively in tumor cells harboring KRAS  mutations,3,4,9,10,11 
sotorasib may provide a therapeutic benefit for patients with KRAS  p.G12C -driven cancers.  
The metabolism and excretion of sotorasib were evaluat ed in bile duct -cannulated male rats after 
a single intravenous (1 mg/kg) or oral (10 mg/kg) dose of sotorasib. Recovery of sotorasib and 
metabolites  was low ( 10) in the study, consistent with extensive metabolism of sotorasib. 
Metabolite profiling by liquid chromatography high -resolution mass spectrometry (LC -HRMS) 
methods identified low amounts of sotorasib and  metabolites  excreted into bile (approximately 
0.4 to 3.4 of dose), feces (approximately 1.0  to 2.2 of dose), and urine (0.4  to 1.7 of 
dose) following both intravenous and oral administration, with metabolites that included 
products of oxidative metabolism and glucuronidation (M3, M4, M16), cysteine and N -acetyl 
cysteine conjugation (M10, M15, M20), reduction (M21), and dealkylation (M24). Refer to the 
IB1 for more information.  
Four sotorasib cl inical studies (20170543, 20190009, 20190135, and 20190147) are currently 
ongoing in subjects with KRAS p.G12C -mutated tumors. In addition, a number of studies in 
healthy volunteers have explored the pharmacokinetics (PK) of sotorasib in a mass -balance 
study, the PK of sotorasib in the fasted versus fed conditions, and the drug -drug interactions.  
Preliminary data are available for phase 1 of the phase 1/2 Study 20170543 that evaluates the 
safety, tolerability, PK, pharmacodynamics, and efficacy of sotorasi b in subjects with KRAS 
p.G12C -mutated advanced solid tumors as monotherapy and in combination with 
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Numb er: 20200362  
Protocol Version 1.0, 09 February 2021   Page 16 of 67 pembrolizumab. As of 01 June 2020, 199 subjects were enrolled in the phase 1 monotherapy 
treatment cohorts; of these, 197 subjects received at least 1 dose of sotorasib (dose range: 180 to 
960 mg).  
1.2. Pharmacokinetics  
Preliminary sotorasib PK data were available as of 20 May 2020 for subjects with a specific 
KRAS  mutation with advanced solid tumors in the dose -exploration part of the first -in-human 
study, with once daily (QD) oral doses ranging from 180 to 960 mg. Dose -related increases in 
exposure on Day 1 were observed in oral QD doses from 180 through 960  mg. Increase in 
exposure was less than dose -proportional on Day 1. There was no accumulation with multipl e 
oral QD dosing for 8 days. Increase in exposure from 180 through 960 mg following oral QD 
dosing was less than dose -proportional on Day 8. Rapid absorption was observed, with time to 
maximum plasma concentration  (tmax) between 1 to 2 hours after oral administration.  
A mass -balance study was conducted to characterize the PK and primary route(s) of elimination 
of 14C-sotorasib and drug -related material, and to estimate the overall recovery of radiolabeled 
material in healthy male subjects after a single oral suspension dose of 720  mg 14C-sotorasib. 
Based upon preliminary analysis of interim data, the mean PK parameter estimates are similar to 
those observed in subjects with advanced solid tumors. The mean cumulative recovery over the 
collection period (0 to 312 hours) was 80.8 , with 74.6  being excreted in the feces and 6.18  
excreted in the urine.  
A food -effect study was conducted to evaluate the PK of sotorasib administered in the fasted and 
fed conditions in healthy subjects. When 360 mg of sotorasib was administered with a high -fat 
meal, area under the plasma concentration -time- curve (AUC) from time zero to infinity  (AUC inf-
) increased 1.38 -fold compared with administration in the fasted condition. The maximum 
observed drug concentration (C max) was c omparable in fasted and fed conditions. Time to peak 
was delayed by 1.25 hours under the fed condition. These results support the administration of 
sotorasib in either the fed or fasted condition.  
Multiple drug -drug interaction studies have been conducted  with sotorasib. Coadministration of 
sotorasib with single doses of metformin, rifampin, and multiple doses of itraconazole resulted in 
no clinically meaningful changes in exposure. Results from coadministration of sotorasib with 
multiple doses of rifampin  or omeprazole indicated that exposure of sotorasib may fall to 
suboptimal levels when administered with a proton -pump inhibitor (PPI) or strong inducers of 
cytochrome P450 (CYP)3A4. Following coadministration with digoxin, systemic exposure of 
digoxin inc reased and caution should be used when sotorasib is administered with substrates of 
P-glycoprotein (P -gp). 
More details of these studies are available in the IB.1 
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Numb er: 20200362  
Protocol Version 1.0, 09 February 2021   Page 17 of 67 1.3. Study Rationale  
The liver plays a significant role in the clearance of many drugs through a variety of oxidative 
and conjugative metabolic pathways and/or through biliary excretions. Alterations of these 
excretory and metabolic activities by hepatic impairment can lead to increased drug exposure 
and toxicity. As outlined in the Food and Drug Administration (FDA) Guidance for Industry,12 
PK studies are recommended in patients with impaired hepatic function if hepatic metabolism 
and/or excretion accounts for 20 of the elimination of a parent drug or active metabolite.  
Results from this study will provide information on the safety, toler ability, and PK of sotorasib 
and guide dosing in subjects with normal hepatic function and in subjects with moderate hepatic 
impairment (Child -Pugh B) and severe hepatic impairment (Child -Pugh C).  
1.4. Benefit -risk Assessment  
The following benefit -risk assessm ent supports the conduct of this clinical study. Refer to the IB1 
for more information.  
1.4.1.  Therapeutic Context  
1.4.1.1.  Key Benefits  
Subjects in the current study  will not receive any health benefit (beyond that of an assessment of 
their medical status) from participating in the study.  
1.4.1.2.  Risks  
Risks of Sotorasib  
Based on clinical and nonclinical toxicity studies of sotorasib, the key safety information to be 
monito red in clinical studies of sotorasib include abnormal liver function tests, renal toxicity, 
anemia, leukocytosis, thyroid abnormalities, and splenomegaly. Clinical signs and symptoms of 
these toxicities observed in clinical and nonclinical studies, along w ith relevant laboratory 
parameters, will be monitored during the study to ensure subjects’ safety.  
Abnormal Liver Function Tests  
Abnormal liver function tests (increased aspartate aminotransferase [AST] and increased alanine 
aminotransferase [ALT]) have b een observed in oncology subjects receiving both sotorasib 
monotherapy and combination therapy with sotorasib and anti -programmed cell death protein 1 
(PD-1) antibody. The events of abnormal liver function blood tests generally resolved in subjects 
upon in terruption of treatment. The risk mitigation plan consists of monitoring liver enzymes, 
with regular measurement of AST, ALT, alkaline phosphatase, and bilirubin to be performed. 
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Numb er: 20200362  
Protocol Version 1.0, 09 February 2021   Page 18 of 67 Specific eligibility criteria and dose -modification guidelines for sotorasib are provided in 
Section  4. 
Renal Toxicity  
Sotorasib -related degeneration/necrosis of renal tubule epithelium was observed in the rat 
repeated -dose toxicology studies. The incidence and severity of tubular degeneration/ necrosis 
was dependent on dose/exposure levels and treatment duration. In the 28 -day study, 2 of 20 
animals at 200 mg/kg (the highest dose tested) had minimal to mild change. In the 3 -month 
study, the same renal change progressed to a chronic change that i nvolved more of the renal 
tubule, which was attributed to higher exposures and longer study duration (60 mg/kg: 7/20 [6 
minimal and 1 mild], 180 mg/kg: 12/19 [5 minimal, 6 mild, and 1 moderate], and 750  mg/kg: 
20/20 [4 minimal, 13 mild, 1 moderate, and 2 m arked]). Partial recovery was confirmed at the 
end of the recovery phase; however, marked tubular degeneration/necrosis was also accompanied 
with interstitial fibrosis and glomerulosclerosis, which are considered irreversible changes. The 
changes in renal tubular injury biomarkers in urine were observed as early as Day 8, with the 
largest magnitude of increase for kidney injury molecule (KIM) -1 and clusterin generally 
occurring at this timepoint, and were observed predominantly in animals at 750 mg/kg.  
The risk mitigation plan consists of monitoring of renal function with measurement of the serum 
creatinine and/or estimated creatinine clearance along with urinalysis examinations. Specific 
eligibility criteria to only include subjects with adequate renal func tion are included, as described 
in Section 4. 
Anemia  
Sotorasib -related decrease in red blood cell (RBC) mass (hemoglobin, RBC count, and 
hematocrit ) was observed in both rat and dog toxicology studies. In the rat studies, decreased 
RBC cell mass was observed inconsistently associated with secondary physiologically 
appropriate increases in reticulocyte counts, and increases in RBC indices and platelet s. 
Increased reticulocytes correlated with minimally increased hematopoiesis in the spleen were 
seen only in the 28 -day rat study. In the dog studies, minimal to mild decreases in RBC mass 
were seen associated with decreased reticulocytes. Due to the small  magnitudes of change, the 
sotorasib -related effects on hematology parameters were considered non -adverse and were 
reversible after a 28 -day recovery in rats; reversibility was expected based on the normal 
regenerative capacity of the hematopoietic system and the absence of overt bone -marrow toxicity 
(eg, hypocellularity).  
The risk mitigation plan consists of monitoring hemoglobin, hematocrit, and associated adverse 
events. Specific eligibility criteria and dose -modification guidelines pertaining to hematol ogy 
parameters are provided in Section 4. 
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Numb er: 20200362  
Protocol Version 1.0, 09 February 2021   Page 19 of 67 Leukocytosis  
Sotorasib -related increased leukocytes were observed in the rat repeated -dose toxicology studies, 
including increases in white blood cell (WBC) count, neutrophils, lymphocytes, monocytes, 
eosinophils, basophils, and large unstained cells with no light microscopic correlates. Due to the 
small magnitudes of change, the sotorasib -related effects on hematology parameters were 
considered non -adverse and were not observed after recovery period. The risk mitigation plan 
consists of monitoring WBC count and differential and associated adverse events.  
Thyroid Dysfunction  
In the 3 -month dog toxicology s tudy (0, 200, and 1000 mg/kg/day administered as 0, 100 and 
500 mg/kg twice daily), there was abnormal content in the gall bladder and microscopic changes 
in the liver, pituitary, or thyroid that were considered to be either non -severely toxic and/or 
adapt ive or secondary responses to hepatocellular enzyme induction.  In the thyroid, mild to 
moderate follicular cell hypertrophy and moderate to marked colloid depletion were observed 
accompanied with decreased thyroid weights. A few animals at 1000 mg/kg/day also had marked 
atrophy of the thyroid. The risk mitigation plan consists of monitoring  thyroid function with 
regular measurement of serum triiodothyronine (T3), free thyroxine (T4), and thyroid -
stimulating hormone (TSH), and for any clinical signs or symp toms concerning for thyroid 
dysfunction.  
Splenomegaly  
Sotorasib -related increase in spleen weights was observed in males at  100 mg/kg in a Good 
Laboratory Practice 28 -day rat toxicology study. At 100 and 200 mg/kg, spleen weights were 
increased up to 21  and these increases were not observed at the end of the 28 -day recovery 
period. Although minimal increased hematopoiesis was observed in the spleen at 200 mg/kg, the 
degree of increased hematopoiesis was interpreted to be insufficient to account for incr eased 
spleen weights. There was no sotorasib -related change in spleen weight in the rat 3 -month study. 
The risk mitigation plan consists of monitoring the size of the spleen (with physical examination) 
and hematology parameters.  
More detailed information a bout the key safety information of sotorasib, including a list of 
adverse drug reactions, may be found in the sotorasib IB.1  
2. OBJECTIVES AND ENDPOINTS  
2.1. Objectives  
The primary objective of the study is:  
 to evaluate the PK of a single oral dose of sotorasib  administered in subjects with 
moderate or severe hepatic impairment compared to subjects with normal hepatic 
function.  
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Numb er: 20200362  
Protocol Version 1.0, 09 February 2021   Page 20 of 67 The secondary objective  of the study is:  
 to evaluate the safety and tolerability of sotorasib  administered in subjects with moderate 
or severe hepatic impairment compared to subjects with normal hepatic function.  
2.2. Endpoints  
2.2.1.  Primary Endpoints  
The primary endpoints of the study are  PK parameters for sotorasib:  
 Cmax 
 AUC from time zero to the last quantifiable concentration (AUC last) 
 AUC inf. 
Additional PK parameters may be calculated.  
2.2.2.  Secondary Endpoints  
The secondary endpoints of the study are:  
 adverse events  
 clinical laboratory eval uations  
 12-lead electrocardiograms (ECGs)  
 vital signs  
 unbound C max (Cmax,u) 
 unbound AUC last (AUC last,u) 
 unbound AUC inf (AUC inf,u) 
 unbound apparent total plasma clearance (CL u/F) 
 unbound apparent volume of distribution during the terminal phase (V z,u/F).  
3. INVESTIGATIONAL PLAN  
3.1. Overall Study Design and Plan  
This will be a Phase 1, parallel -arm, multi -center (US), open -label, non -randomized study to 
evaluate the PK of a single oral dose of sotorasib administered in subjects with normal hepatic 
function (control ) and in subjects with moderate or severe hepatic impairment (according to 
Child -Pugh classification) under fasted conditions. Subjects who meet eligibility requirements 
will be assigned to 1 of 3 groups as shown in Table 1. The Child -Pugh classification will be 
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Numb er: 20200362  
Protocol Version 1.0, 09 February 2021   Page 21 of 67 based on the Child -Pugh score at Screening. The Child -Pugh scores classification is described in 
Appendix 3.  
Attempts will be made to match for age (mean  10 years), sex, and body mass index (mean  
20) between normal and hepatically impaired groups. Up to 8 subjects can be enrolled in 
Group 1 to satisfy matching criteria. Up to 8 subjects will be enrolled in Groups 2 and 3 to 
ensure 6 evaluable subjects. Subjects will maintain the same group assignment throughout the 
study.  
Table 1: Classification of Hepatic Impairment Groups  
Group  Degree of Hepatic Impairment  Number of Subjects  
1 Normal function (no impairment)  6 to 12  
2 Moderate impairment (Child -Pugh Class B)  6 to 8  
3 Severe impairment (Child -Pugh Class C)  6 to 8  
The classification is based on Child -Pugh - scores as per Figg and Dukes.13 Child -Pugh scores classification is described in 
Appendix 3. 
Potential subjects will be screened to assess their eligibility to enter the study within 28  days 
prior to the dose administration. Subjects will be admitted into the st udy site on Day  1 and be 
confined until discharge on Day  8. On Day 1, after at least a 10 -hour fast, all subjects will 
receive a single oral dose of 960 mg sotorasib (8 x 120-mg tablets).  
The total duration of study participation for each subject (from Sc reening through end of study 
[EOS]) is anticipated to be approximately 4 weeks.  
The start of the study is defined as the date the first enrolled subject signs an Informed Consent 
Form (ICF). The point of enrollment occurs at the time of subject number allo cation. The end of 
the study is defined as the date of the last subject’s last assessment (scheduled or unscheduled).  
An overview of the study design is shown in Figure  1. 
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Numb er: 20200362  
Protocol Version 1.0, 09 February 2021   Page 22 of 67 Figure  1: Study Schematic  
A Schedule of Assessments is presented in Appendix  8. 
3.2. Discussion of Study Design  
This study has been designed in accordance with the FDA regulatory guida nce for the study of 
PK in subjects with impaired hepatic function.12  
A single -dose, parallel design is the standard design to investigate the PK of a drug in subjects 
with hepatic impairment. A parallel design is required to include subjects with hepatic 
impai rment and control subjects with normal hepatic function.  Control healthy subjects with 
normal hepatic function will be enrolled in this study to serve as a reference group for 
interpretation of the results. The safety and PK assessments are standard param eters for clinical 
studies in drug development.  
This study will be open label because the study endpoints are not considered subjective.  
3.3. Selection of Doses in the Study  
The 960 -mg dose was selected for the present study because this is the recommended dose  in the 
Phase 2 portion of an ongoing clinical study (Study 20170543). Sotorasib is primarily 
metabolized by CYP3A4. Study 20190318 evaluated the impact of itraconazole (a strong 
CYP3A4 inhibitor) on the PK of 360 mg sotorasib in healthy subjects. Geometri c least squares 
mean ratio (test/reference) of sotorasib AUC inf and C max were 1.261 and 1.040, respectively, 
when comparing sotorasib coadministered with itraconazole (test) and sotorasib administered 
alone (reference). Doses of 360 mg sotorasib were safe and well tolerated when coadministered 
with 200 mg itraconazole to healthy subjects.  The mean magnitude of the relative effect in this 
hepatic impairment study is anticipated to be similar to the past DDI study with a potent 
CYP3A4 inhibitor.  A substudy i n Study 20170543 evaluated the food effect on 960 mg sotorasib 
PK in patients with advanced solid tumors. Coadministration with high -fat meals resulted in a 
geometric least squares mean ratio (test/reference) of 1.25 and 0.66 for AUC from time zero to 
Study day  
-28 
 -1 
 1 
 2 
 3 
 8 
Resident in the Clinical Research Unit  
Check -in 
960 mg sotorasib  
Discharge/ End 
of Study  
PK sample collection  
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Numb er: 20200362  
Protocol Version 1.0, 09 February 2021   Page 23 of 67 24 hours postdose (AUC 0-24) and C max, respectively. Exposure in this hepatically impaired 
population is anticipated to be similar to those exposures observed in Study 20190318 and food -
effect substudy in Study 20170543.  
There have been no dose -limiting toxicit ies observed with sotorasib monotherapy at 960  mg in 
subjects with advanced solid tumors with the KRAS p.G12C mutation. Please refer to the IB1 for 
more information.  
4. SELECTION OF STUDY P OPULATION  
4.1. Inclusion Criteria  
Subjects must satisfy all of the following criteria prior to enrollment unless otherwise stated:  
All subjects:  
1. Subject has provided informed consent before initiation of any study -specific 
activities/procedures.  
2. Male subjects or female subjects, between 18 and 70  years of age (inclusive) at the time 
of Screening.  
3. Body mass index between 18.0 and 38.0 kg/m2 (inclusive) at the time of Screening.  
4. Females of nonchildbearing potential defined as permanently sterile (ie, due to 
hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or postmenopausal 
(defined as at least 45 years of age with amenorrhea for 12 months without an alternative 
medical cause and follicle -stimulating hormone [FS H] level  40 mIU/mL).  
Subjects with Normal Hepatic Function Only (Group 1)  
5. In good health, determined by no clinically significant findings from medical history, 
physical examination, 12 -lead ECG, vital signs measurements, and clinical laboratory 
evaluati ons (congenital nonhemolytic hyperbilirubinemia [eg, suspicion of Gilbert’s 
syndrome based on total and direct bilirubin] is not acceptable) as assessed by the 
Investigator (or designee).  
Subjects with Hepatic Impairment Only (Groups 2 and 3)  
6. Child -Pugh B (Group 2) or C (Group 3) classification ( Appendix 3) defined by both 
Screening and Check -in clinical laboratory values and clinical examination findings . 
7. Clinically stable hepatic disease in the opinion of the Investigator (eg, not including 
rapidly progressive primary or secondary hepatic malignancy). Documented medical 
history of chronic liver disease including, but not limited to, liver cirrhosis, hepa titis B 
infection, alcoholic liver disease, or previous hepatitis C virus (HCV) infection (HCV 
RNA to be undetectable in all enrolled subjects at Screening) or as assessed by the 
Investigator (or designee).  
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Numb er: 20200362  
Protocol Version 1.0, 09 February 2021   Page 24 of 67 8. Subjects with moderate or severe hepatic impairme nt may have medical findings 
consistent with their hepatic dysfunction, as determined by medical history, physical 
examination, 12 -lead ECG, vital sign measurements, and clinical laboratory evaluations 
at Screening and Check -in.  Subjects with abnormal fin dings considered not clinically 
significant by the Investigator will be eligible.  
4.2. Exclusion Criteria  
Subjects will be excluded from the study if they satisfy any of the following criteria prior to 
enrollment unless otherwise stated:  
All subjects:  
1. Any unsta ble medical condition, defined as having been hospitalized within 21 days 
before Check -in, major surgery within 6 months before Check -in, or otherwise unstable 
in the judgment of the Investigator and/or Medical Monitor (eg, risk of complications or 
adverse  events unrelated to study participation).  
2. History or evidence, at Screening or Checkin -, of clinically significant disorder, 
conditi on, or disease not otherwise excluded that, in the opinion of the Investigator (or 
designee), would pose a risk to subject safety or interfere with the study evaluation, 
procedures, or completion.  
3. Venous thromboembolic disease in the last 6 months.  
4. History of malignancy of any type, with the exception of the following: in situ cervical 
cancer or surgical excised nonmelanomatou s skin cancers more than 5 years before 
receiving sotorasib.  
5. History or evidence of clinically significant arrhythmia at Screening, including any 
clinically significant findings on the ECG taken at Check -in.  
6. History suggestive of esophageal (including eso phageal spasm, esophagitis), gastric, or 
duodenal ulceration or bowel disease (including but not limited to peptic ulceration, 
gastrointestinal bleeding, ulcerative colitis, Crohn’s disease, or irritable bowel 
syndrome); or a history of gastrointestinal su rgery other than uncomplicated 
appendectomy cholecystectomy, and hernia repair.  
7. Inability to swallow oral medication or history of malabsorption syndrome.  
8. History of significant hypersensitivity, intolerance, or allergy to any drug compound, 
food, or other  substance, unless approved by the Investigator (or designee) and in 
consultation with the Sponsor.  
9. Poor peripheral venous access.  
10. Estimated glomerular filtration rate (eGFR) less than 45 mL/min/1.73 m2 as calculated by 
the Modification of Diet in Renal Di sease (MDRD) equation, at Screening or Checkin.  
11. Positive human immunodeficiency virus test at Screening.  
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Numb er: 20200362  
Protocol Version 1.0, 09 February 2021   Page 25 of 67 12. Use of any over -the-counter or prescription medications within 30 days or 5 half -lives 
(whichever is longer) prior to study Day 1 that was not reviewed and approved by the 
Investigator (or designee) and the Sponsor, which include known CYP3A4 and P -gp-
sensitive substrates (with a narrow therapeutic window) and strong inducers of CYP3A4 
(including herbal suppl ements such as St. John’s wort),  with below exceptions.  
a. Ibuprofen and hormone -replacement therapy (eg, estrogen, thyroid) will be 
allowed.  
b. Therapies for hepatic disease and treatments of associated disorders that have 
been stable for at least 30 days prior to study drug administration and deem ed 
acceptable, by the Investigator (or designee) and the Sponsor, to be given 
concurrently with sotorasib during the study period.  
13. Administration of an approved (authorized) Coronavirus Disease 2019 (COVID -19) 
vaccine in the past 28 days prior to dosing or  a COVID -19 vaccine given Emergency Use 
Approvals (US) in the past 30 days prior to dosing.  
14. All herbal medicines (eg, St. John’s wort), vitamins, and supplements consumed by the 
subject within the 30 days prior to enrollment, unless deemed acceptable by t he 
Investigator (or designee) and in consultation with the Sponsor.  
15. Consumption of foods and beverages containing poppy seeds, grapefruit, or Seville 
oranges within 7 days prior to Check -in. 
16. History of alcoholism or drug/chemical abuse within the last 3 mo nths prior to Check -in. 
17. Alcohol consumption from 48 hours prior to Check -in. 
18. Regular alcohol consumption of  14 units per week for males and  7 units for females. 
One unit of alcohol equals 12 oz (360 mL) beer, 1½ oz (45 mL) liquor, or 5  oz (150 mL) 
wine.  
19. Use of tobacco - or nicotine -containing product s within 3 months prior to Check -in. 
20. Positive test for illicit drugs, cotinine (tobacco or nic otine use), and/or a lcohol use at 
Check -in. 
21. Consumption of caffeine -containing foods and beverages within 48 hours prior to Check -
in. 
22. Female subjects with a positive pregnancy test at Screening or Check -in.  
23. Male subjects (with a female partner of childbe aring potential) who are unwilling to 
practice sexual abstinence (refrain from heterosexual intercourse) or unwilling to adhere 
to contraceptive requirements through 7 days after sotorasib dosing (see Appendix 4).  
24. Unwilling to abstain from sperm donation and ovum donation through 7 days after 
sotorasib dosing (see Appendix 4). 
25. Male subjects with a female partner of childbearing potential and not willing to inform 
his partner of his participation in this clinical study.  
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Numb er: 20200362  
Protocol Version 1.0, 09 February 2021   Page 26 of 67 26. Male subjects with a pregnant partner or part ner planning to become pregnant who are 
unwilling to practice abstinence or use a condom for 7 days after sotorasib dosing.  
27. Subject has received a dose of an investigational drug (new chemical entity) within the 
past 30 days or 5 half -lives, whichever is l onger, prior to Check -in. 
28. Have previously completed or withdrawn from this study or any other study investigating 
sotorasib or have previously received the investigational product.  
29. Donation of blood from 3 months prior to Check -in, plasma from 2 weeks pri or to Check -
in, or platelets from 6 weeks prior to Check -in. 
30. Receipt of blood products within 2 months prior to Check -in. 
31. Unwilling to abide with study restrictions.  
32. Subjects who, in the opinion of the Investigator (or designee), should not participate in 
this study.  
Subjects with Normal Hepatic Function Only (Group 1)  
33. Positive hepatitis B or hepatitis C panel at Screening. Subjects whose results are 
compatible with prior immunity (vaccination or prior infection) may be included.  
34. ALT or AST  upper limit of  normal (ULN) at Screening or Check -in. 
35. Total bilirubin levels  ULN at Screening or Check -in. 
36. A QT interval corrected for heart rate based on the Fridericia correction (QTcF) interval 
 450 msec in male subjects or  470 msec in female subjects or history /evidence of long 
QT syndrome at Screening or Check -in, confirmed by calculating the mean of the 
original value and 2 repeats.  
Subjects with Hepatic Impairment Only (Groups 2 and 3)  
37. Values outside the normal range for liver function tests that are not cons istent with their 
hepatic condition, as determined by the Investigator (or designee).  
38. A QTcF interval  470 msec in male subjects or  480 msec in female subjects at 
Screening or Check -in, confirmed by calculating the mean of the original value and 
2 repea ts. 
39. Use of a new medication, or a change in dose, for the treatment, or worsening of, hepatic 
encephalopathy within 30 days prior to Check -in. 
40. Recent history of, or the treatment of, gastrointestinal bleeding (within the past 6 
months).  
41. Presence of a portosystemic shunt.  
42. Recent history of paracentesis within 30 days prior to Check -in. 
43. Current functioning organ transplant or are waiting for an organ transplant.  
44. Evidence of severe ascites.  
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Numb er: 20200362  
Protocol Version 1.0, 09 February 2021   Page 27 of 67 45. History within 60 days prior to the Screening visit or current sy mptoms of hepatic 
encephalopathy Grade 2 or above.  
4.3. Screen Failures and Rescreening  
Screen failures are defined as subjects who consent to participate in the clinical study but are not 
subsequently enrolled in the study. A minimal set of screen failure info rmation will be collected 
that includes demography, screen failure details, eligibility criteria, medical history, prior 
therapies, and any serious adverse events.  
If a subject has not met all eligibility criteria the subject will be registered as a screen  fail. Screen 
fail subjects may be eligible for rescreening one time, at the discretion of the Investigator in 
consultation with the Sponsor.  
Rescreened subjects must first be documented as screen failures, and subsequently registered as 
rescreens. Once th e subject is registered as rescreened, a new 20 -day Screening window will 
begin. Subjects will retain the same subject identification number assigned at the original 
Screening. If the rescreening period begins more than 30 days after the original signing o f the 
ICF, all Screening procedures including informed consent must be repeated.  
4.4. Subject Number and Identification  
Subjects will have a unique identification number used at Screening. Subjects will be assigned a 
subject number prior to the first dosing oc casion. Assignment of subject numbers will be in 
ascending order and no numbers will be omitted (eg,  Subjects  0101, 0102, 0103). Replacement 
subjects ( Section  4.5) will be assigned a subject number corresponding to the number of the 
subject he/she is replacing plus 1000 (eg,  Subject  1101 replaces Subject  0101).  
Subjects will be identified by subject number only on all study documentati on. A list identifying 
the subjects by subject number will be kept in the Site Master File.  
4.5. Subject Withdrawal and Replacement  
A subject is free to withdraw from the study at any time. In addition, a subject will be withdrawn 
from dosing if any of the foll owing criteria are met:  
 change in compliance with any inclusion/exclusion criterion that is clinically relevant and 
affects subject safety as determined by the Investigator (or designee)  
 noncompliance with the study restrictions that might affect subject s afety or study 
assessments/objectives, as considered applicable by the Investigator (or designee)  
 any clinically relevant sign or symptom that, in the opinion of the Investigator (or 
designee), warrants subject withdrawal.  
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Numb er: 20200362  
Protocol Version 1.0, 09 February 2021   Page 28 of 67 If a subject is withdrawn from th e study, the Sponsor will be notified and the date and reason(s) 
for the withdrawal will be documented in the subject’s electronic Case Report Form (eCRF). If a 
subject is withdrawn, efforts will be made to perform all EOS assessments, if possible 
(Appendix  8). Other procedures may be performed at the Investigator’s (or designee’s) and/or 
Sponsor’s discretion. If the subject is in -house, these procedures should be performed before the 
subject is discharged from the clinic. The Investigator (or designee) may also request that the 
subject return for an additional follow -up visit. All withdrawn subjects will be followed until 
resolution of all their adverse e vents or until the unresolved adverse events are judged by the 
Investigator (or designee) to have stabilized.  
Subjects who are withdrawn for reasons not related to study drug may be replaced following 
discussion between the Investigator and the Sponsor. Su bjects withdrawn as a result of adverse 
events thought to be related to the study drug will generally not be replaced.  
4.6. Study Termination  
The Sponsor may stop the study or study site participation in the study for medical, safety, 
regulatory, administrative , or other reasons consistent with applicable laws, regulations, and 
GCP. Both the Sponsor and the Investigator reserve the right to terminate the Investigator's 
participation in the study according to the Clinical Trial Agreement. The Investigator is to n otify 
the Institutional Review Board (IRB) in writing of the study's completion or early termination 
and send a copy of the notification to the Sponsor. The Sponsor reserves the unilateral right, at 
its sole discretion, to determine whether to supply inves tigational product and by what 
mechanism, after termination of the study.  
In addition, the study may be terminated by the Sponsor at any time and for any reason. If the 
Sponsor decides to terminate the study, they will inform the Investigator as soon as po ssible.  
5. STUDY TREATMENTS  
Study treatment is defined as any investigational product, non -investigational product, placebo, 
or medical device intended to be administered to a study subject according to the study protocol.  
Note that in several countries, inve stigational product and non -investigational product are 
referred to as investigational medicinal product and non -investigational medicinal product, 
respectively.  
5.1. Investigational Product  
The IMP will be supplied by the Sponsor. The Investigational Product Instruction Manual, a 
document external to this protocol, contains detailed information regarding the storage, 
preparation, destruction, and administration of the IMP shown in  Table  2. 
All supplies of investigational product, both bulk and subject -specific, will be stored in 
accordance with the manufacturer’s instructions or pharmacy instructions. Until dispensed to the 
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Numb er: 20200362  
Protocol Version 1.0, 09 February 2021   Page 29 of 67 subjects, the investigational and non -investigational products will be stored at the study site in a 
location that is locked with restricted access.  
Table  2: Investigational Product(s)  
Study Treatment Name  Investigational Medicinal Product:  
 Sotorasib  
Unit Strength and Formulation  120-mg tablet  
Dosage Level  960 mg (8 x 120 mg)  
Route of Administration  Oral 
Accountability  The quantity administered, date administered, and lot 
number of investigational product are to be recorded on 
each subject's Case Report Form.  
Dosing Instructions  The Investigator/designee will administer the treatment after 
the completion of all predose procedures and after a fast of 
at least 10 hours. Eight tablets of sotorasib should be taken 
with up to 16 ounces (480 mL) of water. Tablets should not 
be broken or  chewed. No food will be given for at least 4 
hours post sotorasib administration.  
Except as part of the dose administration, subjects will restrict their consumption of water for 1 
hour prior to dosing and for 2 hours after dosing; at all other times du ring the study, subjects may 
consume water as desired. Subjects will continue fasting for at least 4 hours postdose.  
Subjects will be dosed while standing and will not be permitted to lie supine for 2 hours after 
administration of IMP, except as necessitat ed by the occurrence of an adverse event(s) and/or 
study procedures.  
5.2. Treatment of Overdose  
Neither the effects of overdose of sotorasib nor an antidote to overdose are known.  
5.2.1.  Medical Devices  
No investigational medical device(s) will be used in this study.  
Other non -investigational medical devices may be used in the conduct of this study as part of 
standard care. Non -investigational medical devices (eg, syringes, sterile needles) that are 
commercially available are not usually provided or reimbursed by the Sponsor (except, for 
example, if required by local regulation). The Investigator will be responsible for obtaining 
supplies of these devices.   
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Numb er: 20200362  
Protocol Version 1.0, 09 February 2021   Page 30 of 67 5.2.2.  Product Complaints  
A product complaint is any written, electronic, or oral communication that alleges deficienci es 
related to the identity, quality, durability, reliability, safety, effectiveness, or performance of a 
drug(s) or device(s) after it is released for distribution to market or clinic by either the Sponsor or 
by distributors and partners for whom the Spons or manufactures the material. This includes  any 
investigational product (sotorasib)  provisioned and/or repackaged/modified by the Sponsor . 
Any product complaint(s) associated with an investigational product (sotorasib) supplied by the 
Sponsor is to be reported according to the instructions provided in the Amgen IPIM.  
5.3. Randomization  
This is a non -randomized study. Subjects will receive their first dose of sotorasib in a gated 
fashion, with at least 3 moderately impaired subjects being dosed first followed by a period of at 
least 2 days before the remaining moderate or severely impaire d subjects are dosed.  
5.4. Blinding  
This is an open -label study.  
5.5. Treatment Compliance  
The following measures will be employed to ensure treatment compliance:  
 All doses will be administered under the supervision of suitably qualified study site staff.  
 Immediate ly after dose administration, visual inspection of the mouth and hands will be 
performed for each subject.  
 At each dosing occasion, a predose and postdose inventory of sotorasib  will be 
performed.  
5.6. Drug Accountability  
The Investigator (or designee) will ma intain an accurate record of the receipt of sotorasib tablets 
received. In addition, an accurate drug disposition record will be kept, specifying the amount 
dispensed to each subject and the date of dispensing. This drug accountability record will be 
avail able for inspection at any time. At the completion of the study, the original drug 
accountability record will be available for review by the Sponsor upon request.  
For each batch of unit doses, the empty used unit dose containers will be discarded upon 
satisfactory completion of the compliance and accountability procedures. Any unused assembled 
unit doses will be retained until completion of the study.  
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Numb er: 20200362  
Protocol Version 1.0, 09 February 2021   Page 31 of 67 At the completion of the study, all unused sotorasib tablets will be returned to the Sponsor, 
retained at t he study site, or disposed of by the study site, per the Sponsor’s written instructions.  
6. CONCOMITANT THERAPIES AND OTHER RESTRICTIONS  
6.1. Concomitant Therapies  
Subjects will refrain from use of any prescription or nonprescription medications/products during 
the study until the EOS, unless the Investigator (or designee) and/or Sponsor have given their 
prior consent.  
Subjects will refrain from use of any PPIs within 5 days or H2 -receptor antagonists within 1 day 
prior to study Day 1 until at least 4 hours after IMP administration.  
For hepatically impaired subjects, treatment for the underlying liver disease and comorbid 
conditions (including prescribed analgesia) will be permitted if prescribed by the subject’s 
personal physician and approved by the Medical Moni tor and Investigator, in consultation with 
the Sponsor as needed. Administration of medications should be withheld for at least 4  hours 
after study drug administration as clinically appropriate, unless needed for treatment of an 
adverse event, at the discr etion of the Investigator. Throughout the study, the Investigator may 
prescribe any concomitant medications or treatments deemed necessary to provide adequate 
supportive care except for those listed in the exclusion criteria.  
Foods and medicines that are k nown strong CYP3A4 inducers (eg, rifampin, corticosteroids, 
anticonvulsants, and St. John’s wort) or CYP3A4 or P -gp substrates with narrow therapeutic 
index are prohibited prior to IMP administration as specified in the exclusion criteria 
(Section  4.2) and during the study until the EOS.  
Ibuprofen  and hormone -replacement therapy are acceptable concomitant medications. The 
administration of any other concomitant medications during the study is prohibited without prior 
approval of the Investigator (or designee), unless its use is deemed necessary for treatment of an 
adverse event. Any medication taken by a subject during the course of the study and the reason 
for its use will be documented in the source data.   
6.2. Diet 
While confined at the study site, subjects will receive a standardized diet at scheduled times that 
do not conflict with other study -related activities. Subjec ts will be fasted overnight (at least 
8 hours) before collection of blood samples for clinical laboratory evaluations.  
Refer to Section  5.1 and Table  2 for diet requirements/restrictions on Day 1.  
Foods and beverages containing poppy seeds, grapefruit, or Seville oranges will not be allowed 
from 7  days p rior to Check -in until EOS.   
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Numb er: 20200362  
Protocol Version 1.0, 09 February 2021   Page 32 of 67 Caffeine -containing foods and beverages will not be allowed from 48  hours before Check -in 
until EOS.   
Consumption of alcohol will not be permitted from 48  hours prior to Check -in until EOS . 
6.3. Smoking  
Subjects will not be permitted to use tobacco or nicotine -containing products within 3  months 
prior to Check -in until the EOS.  
6.4. Exercise  
Subjects are required to refrain from strenuous exercise from 7  days before Check --in until the 
EOS. Subjects will otherwise maintain their normal level of physical activity during this time (ie, 
will not begin a new exercise program nor participate in any unusually strenuous physical 
exertion).  
6.5. Blood Donation  
Subjects are required to r efrain from donation of blood from 3 months prior to Check -in, plasma 
from 2 weeks prior to Check -in, and platelets from 6 weeks prior to Check -in until 3  months 
after the EOS.  
7. STUDY ASSESSMENTS AND PROCEDURES  
Every effort will be made to schedule and per form the procedures as closely as possible to the 
nominal time, giving considerations to appropriate posture conditions, practical restrictions, and 
the other procedures to be performed at the same timepoint.  
The highest priority procedures will be perform ed closest to the nominal time. The order of 
priority for scheduling procedures around a timepoint is (in descending order of priority):  
 dosing  
 PK blood samples  
 safety assessments (ECGs will be scheduled before vital signs measurements)  
 any other procedure s. 
Where activities at a given timepoint coincide, consideration must be given to ensure that the 
following order of activities is maintained: ECGs, vital signs, and safety labs.  
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Numb er: 20200362  
Protocol Version 1.0, 09 February 2021   Page 33 of 67 7.1. Pharmacokinetic Assessments  
7.1.1.  Pharmacokinetic Blood Sample Collection and Proce ssing  
Blood samples (approximately 1  x 4 mL for sotorasib, approximately 1 x 4 mL for metabolites, 
and approximately 1 x 4 mL for unbound sotorasib) will be collected by venipuncture or 
cannulation at the times indicated in the Schedule of Assessments in Appendix  8. Proce dures for 
collection, processing, and shipping of PK blood samples will be detailed in a separate 
document.  
Any blood sample collected according to the Schedule of Assessments ( Appendix  8) can be 
analyzed for any of the tests outlined in the protocol and for any tests necessary to minimize 
risks to study subjects. This includes testing to ensure analytical methods produce reliable and 
valid data throughou t the course of the study. This can also include, but is not limited to, 
investigation of unexpected results, incurred sample reanalysis, and analyses for method transfer 
and comparability.  
7.1.2.  Analytical Methodology  
Plasma concentrations of sotorasib and met abolites will be determined using validated analytical 
procedures. Specifics of the analytical method will be provided in a separate document.  
Unbound fraction of sotorasib will be determined using an established plasma protein binding 
assay and analytical  procedure. Specifics of the methods will be provided in a separate 
document.   
7.2. Safety and Tolerability Assessments  
7.2.1.  Adverse Events and Serious Adverse Events: Time Period and Frequency for 
Collecting and Reporting Safety Event Information  
Adverse event def initions, assignment of severity and causality, and procedures for reporting 
serious adverse events are detailed in Appendix 1. 
The condition of each sub ject will be monitored from the time of signing the ICF to EOS. If an 
event is reported as beginning prior to signing of the ICF or occurs prior to initiation of study 
treatment on Day 1 and is assessed as not related to study procedures by the Investigato r (or 
designee), the event will be recorded as subject medical history. Any events occurring after study 
drug administration on Day 1 through EOS will be reported as adverse events. Subjects will be 
observed for any signs or symptoms and asked about their condition by open questioning, such 
as “How have you been feeling since you were last asked?”, at least once each day while resident 
at the study site and at each study visit. Subjects will also be encouraged to spontaneously report 
adverse events occurrin g at any other time during the study.  
Adverse Events  
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Numb er: 20200362  
Protocol Version 1.0, 09 February 2021   Page 34 of 67 The adverse event grading scale to be used in this study is described in Appendix 1. 
The Investigator is responsible for ensuring that all non -serious adverse events observed by the 
Investigator or reported by the subject (whether reported by the subject voluntarily or upon 
questioning, or noted on physical examination) from enrollment through  EOS are 
recorded/reported using the appropriate eCRF.  
Serious Adverse Events  
The Investigator is responsible for ensuring that all serious adverse events observed by the 
Investigator or reported by the subject that occur after signing of the ICF through 3 0 days after 
the last dose of study treatment or the EOS (whichever is later) are reported using the appropriate 
eCRF and reported on the paper -based - Serious Adverse Event Report Form (described in  
Appendix 1). 
All serious adverse events will be collected, recorded, and reported to the Sponsor within 
24 hours of the Investigator’s knowledge of the event. The Investigator will submit any updated 
serious adverse event data to the Sponsor within 24 hours of it being available.  
Serious Adverse Events After the Protocol -required Reporting Period  
There is no requirement to monitor study subjects for serious adverse events following the 
protocol -required repor ting period or after EOS. However, these serious adverse events can be 
reported to Amgen. Per local requirements in some countries, Investigators are required to report 
serious adverse events that they become aware of after EOS. If serious adverse events a re 
reported, the Investigator is to report them to the Sponsor within 24 hours following the 
Investigator’s knowledge of the event using the paper -based Serious Adverse Event Report 
Form.  
Serious adverse events reported outside of the protocol -required re porting period will be 
captured within the Sponsor’s safety database as clinical trial cases and handled accordingly 
based on relationship to investigational product.  
Method of Detecting Adverse Events and Serious Adverse Events  
Care will be taken not to  introduce bias when detecting adverse events and/or serious adverse 
events. Open -ended and non -leading verbal questioning of the subject is the preferred method to 
inquire about adverse event occurrence.  
Follow -up of Adverse Events and Serious Adverse Eve nts 
After the initial adverse event/serious adverse event report, the Investigator is required to 
proactively follow each subject at subsequent visits/contacts. All adverse events and serious 
adverse events will be followed, where possible, until resolutio n, stabilization, until the event is 
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Numb er: 20200362  
Protocol Version 1.0, 09 February 2021   Page 35 of 67 otherwise explained, or the subject is lost to follow -up. This will be completed at the 
Investigator’s (or designee’s) discretion.  
All new information for previously reported serious adverse events must be sent to Amgen  
within 24 hours following knowledge of the new information. If specifically requested, the 
Investigator may need to provide additional follow -up information, such as discharge summaries, 
medical records, or extracts from the medical records. Information p rovided about the serious 
adverse event must be consistent with that recorded on the eCRF.  
Regulatory Reporting Requirements for Serious Adverse Events  
If subject is permanently withdrawn from protocol -required therapies because of a serious 
adverse event,  this information must be submitted to the Sponsor.  
Prompt notification by the Investigator to the Sponsor of serious adverse events is essential so 
that legal obligations and ethical responsibilities toward the safety of subjects and the safety of a 
study  treatment under clinical investigation are met.  
The Sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study treatment under clinical investigation. The 
Sponsor will comply  with country -specific regulatory requirements relating to safety reporting to 
the regulatory authority, IRBs/Independent Ethics Committees , and Investigators.  
Individual safety reports must be prepared for suspected unexpected serious adverse reactions 
according to local regulatory requirements and Sponsor policy and forwarded to Investigators as 
necessary.  
An Investigator who receives an individual safety report describing a serious adverse event or 
other specific safety information (eg, summary or listin g of serious adverse events) from the 
Sponsor will file it along with the IB and will notify the IRB, if appropriate according to local 
requirements.  
Safety Monitoring Plan  
Subject safety will be routinely monitored as defined in the Sponsor’s safety surve illance and 
signal management processes.  
Pregnancy and Lactation  
Details of all pregnancies and/or lactation in female subjects will be collected after the start of 
study treatment and until 7 days after sotorasib dosing. Details of all pregnancies in fema le 
partners of male subjects will be collected after the start of study treatment until 7 days after 
sotorasib dosing.  
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Numb er: 20200362  
Protocol Version 1.0, 09 February 2021   Page 36 of 67 If a pregnancy and/or lactation is reported, the Investigator is to inform Amgen within 24 hours 
of learning of the pregnancy and/or lact ation and is to follow the procedures outlined in  
Appendix 5. Amgen Global Patient Safety will follow -up with the Investigator regarding 
additional information that may be requested.  
Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, st illbirth, congenital 
anomalies, ectopic pregnancy) are considered serious adverse events.  
Further details regarding pregnancy and lactation are provided in Appendix 5. 
7.2.2.  Clinical Laboratory Evaluations  
Blood and urine samples will be collected for clinical laboratory evaluations (including clinical 
chemistry, hematology, urinalysis, and serology) at the times indicated in the Schedule of 
Assessments in Appendix  8. Clinical laboratory evaluations are listed in Appendix 2. 
The Investigator is responsible for reviewing laboratory test results and recording any clinically 
relevant changes occurring during the study in the eCRF. The Investigator must determine 
whether an abnormal value in an in dividual study subject represents a clinically significant 
change from the subject’s baseline values. In general, abnormal laboratory findings without 
clinical significance (based on the Investigator’s judgement) are not to be recorded as adverse 
events. H owever, laboratory value changes that require treatment or adjustment in current 
therapy are considered adverse events. Where applicable, clinical sequelae (not the laboratory 
abnormality) are to be recorded as the adverse event.  
Subjects will be asked to provide urine samples for drugs of abuse screen and cotinine test, and 
will undergo an alcohol test  at the times indicated in the Schedule of Assessments in Appendix  8. 
For all female subjects, a pregnancy test and FSH screen for postmenopausal women will be 
performed at the times indicated in the Schedule of Assessments in Appendix  8.  
An Investigator (or designee) will perform a clinical assessment of all clinical laboratory data.  
7.2.3.  Vital Signs  
Supine blood pressure, supine pulse rate, respiratory rate, and oral body temperature will be 
assessed at the times indicated in the Schedule of Assessments in Appendix  8. Vital signs may 
also be performed at other times if judged to be clinically appropriate or if the ongoing review of 
the data suggests a more detailed assessment of vital signs is required.  
All measurements will be performed singly and re peated once if outside the relevant clinical 
reference range.  
Subjects must be supine for at least 5  minutes before blood pressure and pulse rate 
measurements. When vital signs are scheduled at the same time as blood draws, the blood draws 
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Numb er: 20200362  
Protocol Version 1.0, 09 February 2021   Page 37 of 67 will be obtained  at the scheduled timepoint, and the vitals will be obtained as close to the 
scheduled blood draw as possible, but prior to the blood draw.  
7.2.4.  12-lead Electrocardiogram  
Resting 12 -lead ECGs will be recorded after the subject has been supine and at rest for at  least 
5 minutes at the times indicated in the Schedule of Assessments in Appendix  8. Single 12 -lead 
ECGs will be repeated twice, and an average taken of  the 3 readings, if either of the following 
criteria apply:  
 QTcF  500 msec  
 QTcF change from the baseline (predose) is  60 msec.  
Additional 12 -lead ECGs may be performed at other times if judged to be clinically appropriate 
or if the ongoing review of the  data suggests a more detailed assessment of ECGs is required. 
The Investigator (or designee) will perform a clinical assessment of each 12 -lead ECG.  
7.2.5.  Physical Examination  
A full physical examination or symptom -directed - physical examination will be performed at the 
timepoints specified in the Schedule of Assessments in Appendix  8.  
8. SAMPLE SIZE AND DATA ANALYSIS  
8.1. Determin ation of Sample Size  
Approximately up to 2 4 subjects will be enrolled, with a minimum of 6 evaluable subjects and a 
maximum of up to 8 subjects in Group 1, and a maximum of 16 subjects enrolled in Groups 2 
and 3 (8 subjects in each hepatic impairment group  to ensure 6 evaluable subjects). The sample 
size of 6 subjects per hepatic impairment group is based on practical considerations and 
consistent with regulatory guidance for studies evaluating the effect of hepatic impairment on the 
PK of an IMP.  
8.2. Analysis Populations  
8.2.1.  Pharmacokinetic Population  
The PK population will include all subjects who received at least 1 dose of sotorasib and have 
evaluable PK data. A subject may be excluded from the PK summary statistics and statistical 
analysis if the subject has an  adverse event of vomiting that occurs at or before 2 times median 
time to maximum concentration or diarrhea within 24 hours of dosing.  
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Numb er: 20200362  
Protocol Version 1.0, 09 February 2021   Page 38 of 67 8.2.2.  Safety Population  
The safety population will include all subjects who received sotorasib and have at least 1 
postdose s afety assessment.  
8.3. Pharmacokinetic Analyses  
The plasma PK parameters of sotorasib will be calculated using standard noncompartmental 
methods.  
The primary PK parameters are C max, AUC last, and AUC inf for sotorasib. Other PK parameters for 
sotorasib  may inclu de time of t max, apparent plasma terminal elimination half -life (t 1/2,z), 
apparent total plasma clearance (CL/F), apparent volume distribution during the terminal 
elimination phase (V z/F), unbound fraction (f u), C max,u, AUC last,u, AUC inf,u, CL u/F, and V z,u/F. A 
linear model will be used to analyze log -transformed primary PK parameters. The data from 
hepatically impaired subjects (Group 2 and 3; tests) and control subjects (normal hepatic 
function [Group 1]; reference) will be included in the analysis. Geome tric mean ratios 
(Test/Reference) for C max and AUC values and associated 90  confidence intervals will be 
estimated.  
Additional parameters may be calculated, and sotorasib metabolites may be analyzed.  Specific 
details will be presented in the Statistical Analysis Plan for this study.  
8.4. Safety Analysis  
The number and percentage of subjects reporting any treatment -emergent adverse events will be 
tabulated by Medical Dictionary for Regulatory Activities system organ class and preferred term. 
Tables of fatal adverse events, serious adverse events, adverse e vents leading to withdrawal from 
investigational product or other protocol -required therapies, and significant treatment -emergent 
adverse events will also be provided. Subject -level data may be provided instead of tables if the 
subject incidence is low.  
Observed values for clinical laboratory data, 12 -lead ECGs, and vital signs will be summarized. 
There will be no formal statistical analysis for safety.  
9. REFERENCES  
1. Amgen. AMG 510 – Investigator’s Brochure. (Version 5.1). 13 January 2021.  
2. Hobbs GA, Der CJ, R ossman KL. RAS isoforms and mutations in cancer at a glance. J Cell 
Sci. 2016;129(7):1287 -1292.  
3. Ostrem JM, Shokat KM. Direct small -molecule inhibitors of KRAS; from structural insights 
to mechanism -based design. Nature Rev Drug Discov. 2016;15(11):771 -785. 
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Numb er: 20200362  
Protocol Version 1.0, 09 February 2021   Page 39 of 67 4. Patricelli MP, Janes MR, Li LS, et al. Selective inhibition of oncogenic KRAS output with 
small molecules targeting the inactive state. Cancer Discov. 2016;6:316 -329. 
5. Canon J, Rex K, Saiki AY, et al. The clinical KRAS (G12C) inhibitor AMG 510 drives anti -
tumour immunity. Nature. 2019;575:217 -223.  
6. The AACR Project GENIE Consortium. AACR Project GENIE: Powering Precision 
Medicine Through an International Consortium. Cancer Discov. 2017;7(8):818 -831. 
7. Biernacka A, Tsongalis PD, Peterson JD, et al. The potenti al utility of re -mining results of 
somatic mutation testing: KRAS status in lung adenocarcinoma. Cancer Genet. 
2016;209(5):195 -198. 
8. Neumann J, Zeindl -Eberhart E, Kirchner T, Jung A. Frequency and type of KRAS mutations 
in routine diagnostic analysis of met astatic colorectal cancer. Pathol Res Pract. 
2009;205(12):858 -862. 
9. Janes MR, Zhang J, Li LS, et al. Targeting KRAS mutant cancers with a covalent 
G12C -specific inhibitor. Cell. 2018;172(3):578 -589. 
10. McDonald ER, de Weck A, Schlabach MR, et al. Project DRIVE : A compendium of cancer 
dependencies and synthetic lethal relationships uncovered by large -scale deep RNAi 
screening. Cell. 2017;170(3):577 -592. 
11. Xie C, Li Y, Li LL, et al. Identification of a new potent inhibitor targeting KRAS in non -
small cell lung canc er cells. Front Pharmacol . 2017;8:823.  
12. Food and Drug Administration. Guidance for Industry Pharmacokinetics in Patients with 
Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and 
Labeling. May 2003.  
13. Figg WD, Dukes GE, Lesesne HR et al. Comparison of quantitative methods to assess 
hepatic function: Pugh’s classification, indocyanine green, antipyrine, and dextromethorphan. 
Pharmacotherapy 1995; 15:693 -700. 
 
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Numb er: 20200362  
Protocol Version 1.0, 09 February 2021   Page 40 of 67 10. APPENDICES  
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Number: 20200362  
Protocol Version 1.0, 09 February 2021  Page 41 of 67 Appendix 1: Safety Events: Definitions and Procedures for Recording, Evaluating, Follow -
up, and Reporting of Adverse Event  
Definition of Adverse Event  
Adverse Event Definition  
 An adverse event is any untoward medical occurrence in a clinical study subject 
irrespective of a causal relationship with the study treatment.  
 Note: An adverse event can therefore be any unfavorable and unintended sign 
(including an abnormal laboratory finding), symptom, or disease (new or 
exacerbated) temporally associated with the use of a treatment, combination 
product, medical device, or procedure.  
 Note: Treatment -emergent adverse even ts will be defined in the Statistical Analysis 
Plan.  
Events Meeting the Adverse Event Definition  
 Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) 
or other safety assessments (eg, electrocardiogram, radiological scans, vital signs 
measurements), including those that worsen from baseline, that are considered 
clinically significant in the medical and scientific judgement of the Investigator (ie, 
not related to progression of underlying disease).  
 Exacerbation of a chronic o r intermittent pre -existing condition including either an 
increase in frequency and/or intensity of the condition.  
 New conditions detected or diagnosed after study treatment administration even 
though it may have been present before the start of the study.  
 Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.  
 Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
treatment or a concomitant m edication. Overdose per se will not be reported as an 
adverse event/serious adverse event unless it is an intentional overdose taken with 
possible suicidal/self -harming intent. Such overdoses are to be reported regardless 
of sequelae.  
Events NOT Meeting the Adverse Event Definition  
 Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that 
leads to the procedure is the adverse event.  
 Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission  to a hospital).  
 Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) 
present or detected at the start of the study that do not worsen.  
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Number: 20200362  
Protocol Version 1.0, 09 February 2021  Page 42 of 67 Definition of Serious Adverse Event  
A Serious Adverse Event is defined as any untoward medical occurrence that 
meets at least 1 of the following serious criteria:  
Results in death (fatal)  
Immediately life -threatening  
The term “life -threatening” in the definition of “serious” refers to an event in which 
the subject was at risk of death at the time of the event. It does not refer to an event, 
which hypothetically might have caused death, if it were more severe.  For instance, 
drug-induced hepatitis that resolved without evidence of hepatic failure would not 
be considered life -threatening - even though drug -induced hepatitis can be fatal.  
Requires in -patient hospitalization or prolongation of existing hospitalization  
In general, hospitalization signifies that the subject has been detained (usually 
involving at least an overnight stay) at the ho spital or emergency ward for 
observation and/or treatment that would not have been appropriate in the 
physician’s office or outpatient setting. Complications that occur during 
hospitalization are adverse events. If a complication prolongs hospitalization o r 
fulfills any other serious criteria, the event is serious. When in doubt as to whether 
“hospitalization” occurred or was necessary, the adverse event is to be considered 
serious. Hospitalization for elective treatment of a pre -existing condition that did  
not worsen from baseline is not considered an adverse event.  
Results in persistent or significant disability/incapacity  
The term “disability” means a substantial disruption of a person’s ability to conduct 
normal life functions. This definition is not in tended to include experiences of 
relatively minor medical significance, such as uncomplicated headache, nausea, 
vomiting, diarrhea, influenza, and accidental trauma (eg, sprained ankle), which 
may interfere with or prevent everyday life functions but do no t constitute a 
substantial disruption.  
Is a congenital anomaly/birth defect  
Other medically important serious event  
Medical or scientific judgement is to be exercised in deciding whether serious 
adverse event reporting is appropriate in other situations such as important medical 
events that may not be immediately life -threatening or result in death or 
hospitalization but may jeopardize the subject or may require medical or surgical 
intervention to prevent 1 of the other outcomes listed in the above defini tion. These 
events are typically to be considered serious.  
Examples of such events include invasive or malignant cancers, intensive treatment 
in an emergency room or at home for allergic bronchospasm, blood dyscrasias or 
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Number: 20200362  
Protocol Version 1.0, 09 February 2021  Page 43 of 67 convulsions that do not result in hospitalization, or development of drug 
dependency or drug abuse.  
Recording Adverse Events and Serious Adverse Events  
Adverse Event and Serious Adverse Event Recording  
 When an adverse event or serious adverse event occurs, it is the responsibility of 
the Investigator to review all documentation (eg, hospital progress notes, 
laboratory, and diagnostics reports) related to the event.  
 The Investigator will then record all relevant adverse event/serious adverse event 
information in the Event electronic Case R eport Form (eCRF).  
 The Investigator must assign the following adverse event attributes:  
o Adverse event diagnosis or syndrome(s), if known (if not known, signs or 
symptoms);  
o Dates of onset and resolution (if resolved);  
o Severity (or toxicity defined below);  
o Assessment of relatedness to the investigational product(s) and/or study -
mandated procedures; and  
o Action taken.  
 If the severity of an adverse event changes from the date of onset to the date of 
resolution, record as a single event with the worst severity on  the appropriate eCRF.   
 It is not acceptable for the Investigator to send photocopies of the subject’s medical 
records to Sponsor in lieu of completion of the appropriate eCRF page.  
 If specifically requested, the Investigator may need to provide additional  follow -
up- information, such as discharge summaries, medical records, or extracts from the 
medical records. In this case, all subject identifiers, with the exception of the 
subject number, will be blinded on the copies of the medical records before 
submis sion to the Sponsor.  
 The Investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. In such cases, the diagnosis (not the 
individual signs/symptoms) will be documented as the adverse event/s erious 
adverse event.  
Evaluating Adverse Events and Serious Adverse Events  
Assessment of Severity  
The Investigator will make an assessment of severity for each adverse event and 
serious adverse event reported during the study. The assessment of severity will be 
based on the Common Terminology Criteria for Adverse Events, Version 5.0 or higher, 
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Number: 20200362  
Protocol Version 1.0, 09 February 2021  Page 44 of 67 which is available at the following location: 
https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm   
Assessment of Causality  
 The Investigator is obligated to assess the relationship between investigational 
product(s), protocol -required therapy and/or study -mandated procedure, and each 
occurrence of each adverse event/serious adverse event.  
 Relatedness means that there are facts or r easons to support a relationship between 
investigational product and the event.  
 The Investigator will use clinical judgement to determine the relationship.  
 Alternative causes, such as underlying disease(s), concomitant therapy, and other 
risk factors, as well as the temporal relationship of the event to study treatment 
administration will be considered and investigated.  
 The Investigator will also consult the Investigator’s Brochure and/or Product 
Information, for marketed products, in his/her assessment.  
 For each adverse event/serious adverse event, the Investigator must document in the 
medical notes that he/she has reviewed the adverse event/serious adverse event and 
has provided an assessment of causality.  
 There may be situations in which a serious advers e event has occurred and the 
Investigator has minimal information to include in the initial report. However, it is 
very important that the Investigator always make an assessment of causality for 
every event before the initial transmission of the serious ad verse event data.  
 The Investigator may change his/her opinion of causality in light of follow -up 
information and send a serious adverse event follow -up report with the updated 
causality assessment.  
 The causality assessment is 1 of the criteria used when de termining regulatory 
reporting requirements.  
Follow -up of Adverse Event and Serious Adverse Event  
 The Investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by the 
Sponsor to elucidate the nature and/or causality of the adverse event or serious 
adverse event as fully as possible. This may include additional laboratory tests or 
investigations, histopathological examinations, or consultation with other health -
care professionals.  
 If a subject is permanently withdrawn from protocol -required therapies because of a 
serious adverse event, this information must be submitted to the Sponsor.  
 If a subject dies during participation in the study the Investigator will provide the 
Sponsor with a copy of any post -mortem findings including histopathology.  
 New or updated information will be recorded in the originally completed eCRF.  
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Number: 20200362  
Protocol Version 1.0, 09 February 2021  Page 45 of 67  The Investigator will submit a ny updated serious adverse event data to the Sponsor 
within 24 hours of receipt of the information.  
Reporting of Serious Adverse Event  
Serious Adverse Event Reporting via Paper Serious Adverse Event Report Form  
 Facsimile transmission of the Serious Adverse Event Report Form (see  Figure 2) is 
the preferred method to transmit this information.  
 In rare circumstances and in the absence of facsimile equipment, notification by 
telephone is acceptable with a copy of the Serious Adver se Event Report Form sent 
by overnight mail or courier service.  
 Initial notification via telephone does not replace the need for the Investigator to 
complete and sign the Serious Adverse Event Report Form within the designated 
reporting time frames.   
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Number: 20200362  
Protocol Version 1.0, 09 February 2021  Page 46 of 67 Figure 2:  Sample Serious Adverse Event Report Form  
 
 

Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Number: 20200362  
Protocol Version 1.0, 09 February 2021  Page 47 of 67  
 

Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Number: 20200362  
Protocol Version 1.0, 09 February 2021  Page 48 of 67  

Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Number: 20200362  
Protocol Version 1.0, 09 February 2021  Page 49 of 67 Appendix 2: Clinical Laboratory Evaluations  
Clinical chemistry:  Hematology:  Urinalysis:  
Alanine aminotransferase  
Albumin  
Alkaline phosphatase  
Aspartate aminotransferase  
Blood urea nitrogen  
Calcium  
Chloride  
Cholesterol  
Creatinine  
Direct bilirubina 
Gamma -glutamyl transferase  
Glucose  
Indirect bilirubina 
Inorganic phosphate  
Potassium  
Sodium  
Total bilirubina 
Total protein  
Uric acid  Hematocrit  
Hemoglobin  
Mean cell hemoglobin  
Mean cell hemoglobin 
concentration  
Mean cell volume  
Platelet count  
Red blood cell (RBC) count  
RBC distribution width  
White blood cell (WBC) count  
WBC differential:  
   Basophils  
   Eosinophils  
   Lymphocytes  
   Monocytes  
   Neutrophils  
 Bilirubin  
Blood  
Color and appearance  
Glucose  
Ketones  
Leukocyte esterase  
Nitrite  
pH 
Protein  
Specific gravity  
Urobilinogen  
 
Serologyb: Drug screenc: Hormone panel - females 
only:  
Hepatitis B surface antibody  
Hepatitis B core antibody  
Hepatitis  B surface antigen  
Hepatitis C antibody  
Hepatitis C virus RNA  
Human immunodeficiency virus 
(HIV -1 and HIV -2) antibodies 
and p24 antigen  Including but not limited to:  
Alcohol (breath, urine, or serum)  
Amphetamines /methamphetamin
es 
Barbiturates  
Benzodiazepi nes 
Cocaine (metabolite)  
Methadone  
Phencyclidine  
Opiates  
Tetrahydrocannabinol/  
cannabinoids  
Tricyclic antidepressants  
Cotinine test  
 Follicle -stimulating hormoneb  
(postmenopausal females only)  
Serum pregnancy test (human 
chorionic gonadotropin)d 
Urine pregnancy testd 
Other Tests : 
Thyroid -stimulating hormoneb 
Total cholesterolb 
Low-density lipoprotein 
cholesterol (indirect)b 
Triglyceridesb 
International normalized ratio 
(INR)e 
Estimated glomerular filtration 
rate (eGFR)f 
 
a Direct and indirect bilirubin will be analyzed if total bilirubin is elevated.  
b Only analyzed at Screening.  
c Only analyzed at Screening and Check -in. Alcohol testing is not included at Screening.  
d Performed in serum at Screening and in urine at all ot her times for all females. A positive urine pregnancy test will be 
confirmed with a serum pregnancy test.  
e INR will be tested if hepatotoxicity is suspected guidelines presented in Appendix 7. 
f Estimated glomerular filtration rate will be calculated by the Modification of Diet in Renal Disease (MDRD) equation.  
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Number: 20200362  
Protocol Version 1.0, 09 February 2021  Page 50 of 67 Appendix 3: Child -Pugh Classification of Sev erity of Cirrhosis  
Finding  Points Scored for Each Observed Finding  
1 2 3 
Encephalopathy1 None  1 or 2 (or 
suppressed with 
medication)  3 or 4 (refractory)  
Ascites2 Absent  Slight or Subject on 
1 medication to 
control ascites  Moderate or Severe 
or Subject on 2 
medications to 
control ascites  
Bilirubin (mg/dL)   2 2 to 3   3 
Albumin (g/dL)   3.5 2.8 to 3.5   2.8 
INR  1.7 1.7 to 2.2   2.2 
Abbreviation: INR  international normalized ratio  
1 Grade 0: normal consciousness, personality, neurological examination, electroencephalogram  
Grade 1: restless, sleep disturbed, irritable/agitated, tremor, impaired handwriting, 5 cycles per second waves  
Grade 2: lethargic, time -disoriented, inappropriate, asterixis, ataxia, slow triphasic waves  
Grade 3: somnolen t, stuporous, place -disoriented, hyperactive reflexes, rigidity, slower waves  
Grade 4: unrousable coma, no personality/behavior, decerebrate, slow 2 to 3 cycles per second delta activity  
2 Ascites is graded according to the following criteria:  
Absent: No a scites detectable by manual investigation  
 Slight: Ascites palpitation doubtful  
 Moderate: Ascites detectable by palpation  
Severe: Necessity of paracentesis, does not respond to medication treatment.  
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Number: 20200362  
Protocol Version 1.0, 09 February 2021  Page 51 of 67 Appendix 4: Contraception Requirements  
All subjects must receive pregnancy prevention counseling and be advised of the risk to the fetus 
if they conceive a child during treatment and for 7 days after sotorasib dosing.  
Additional medications given during the study may alter the contraceptive requirements. The 
Investigator must discuss these contraceptive changes with the subject.  
Definitions  
 
Women of Childbearing Potential: premenopausal females who are anatomically and 
physiologically capable of becoming pregnant following men arche.  
 
Women of Nonchildbearing Potential:  
1. Surgically sterile: females who are permanently sterile via hysterectomy, bilateral 
salpingectomy, and/or bilateral oophorectomy by reported medical history and/or medical 
records. Surgical sterilization to hav e occurred a minimum of 6 weeks, or at the 
Investigator’s discretion, prior to Screening.  
2. Postmenopausal: Females at least 45 years of age with amenorrhea for 12 months 
without an alternative medical reason with confirmatory follicle -stimulating hormone 
(FSH) levels of  40 mIU/mL. The amenorrhea should not be induced by a medical 
condition such as anorexia nervosa, hypothyroid disease or polycystic ovarian disease, or 
by extreme exercise. It should not be due to concomitant medications that may have 
induc ed the amenorrhea such as oral contraceptives, hormones, gonadotropin -releasing 
hormones, anti -estrogens, or selective estrogen receptor modulators.  
 
Fertile male: a male that is considered fertile after puberty.  
 
Infertile male: permanently sterile male  via bilateral orchiectomy.  
 
Contraception Requirements  
 
Female Subjects  
 
Female subjects who are of nonchildbearing potential will not be required to use contraception. 
Female subjects are required to refrain from donation of ovum from Check -in until 7 days after 
sotorasib dosing.  
 
Male Subjects:  
 
Male subjects (even with a h istory of vasectomy) with partners of childbearing potential must 
use a male barrier method of contraception (ie, male condom with spermicide) in addition to a 
second method of acceptable contraception by female partner from Check -in until 7 days after 
sotorasib dosing. Acceptable methods of contraception for female partners include:  
 
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Number: 20200362  
Protocol Version 1.0, 09 February 2021  Page 52 of 67  hormonal injection  
 combined oral contraceptive pill or progestin/progestogen -only pill  
 combined hormonal patch  
 combined hormonal vaginal ring  
 surgical method (bilateral tubal ligation or regulatory approved method of hysteroscopic 
bilateral tubal occlusion)  
 hormonal implant  
 hormonal or non -hormonal intrauterine device  
 over-the-counter sponge with spermicide  
 cervical cap with spermicide  
 diaphragm with spermicide.  
 
Male subjects are required to refrain from donation of sperm from Check -in until 7 days after the 
EOS .  
 
Sexual Abstinence  
 
Subjects who practice true abstinence, because of the subject’s lifestyle choice (ie, the subject 
should n ot become abstinent just for the purpose of study participation), are exempt from 
contraceptive requirements. Periodic abstinence (eg, calendar, ovulation, sympto -thermal, 
postovulation methods) and withdrawal are not acceptable methods of contraception.  
 
For subjects who practice true abstinence, subjects must be abstinent for at least 6 months prior 
to Screening and must agree to remain abstinent from the time of signing the Informed Consent 
Form (ICF) until 7 days after sotorasib dosing .  
 
Same -sex Relat ionships  
 
For subjects who are exclusively in same -sex relationships, contraceptive requirements do not 
apply.  
A subject in a same -sex relationship at the time of signing the ICF must agree to refrain from 
engaging in a heterosexual relationship from the t ime of signing the ICF until 7 days after 
sotorasib dosing.  
 
 
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Number: 20200362  
Protocol Version 1.0, 09 February 2021  Page 53 of 67 Appendix 5: Collection of Pregnancy and Lactation Information  
Collection of Pregnancy Information  
Female Subjects Who Become Pregnant  
 Investigator will collect pregnan cy information on any female subject who becomes 
pregnant while taking protocol -required therapies through 7 days after sotorasib dosing.  
 Information will be recorded on the Pregnancy Notification Form (see Figure 3). The 
form must be submitted to Amgen Global Patient Safety within 24 hours of learning of a 
subject’s pregnancy. (Note: Sites are not required to provide any information on the 
Pregnancy Notification Form that violates the country or regions local privacy laws).  
 After obtaining the female subject’s informed consent for release of pregnancy and infant 
health information, the Investigator will collect pregnancy and infant health information 
and complete the pregnancy questionnaire for any female subject who becomes pregnant 
while taking protocol -required therapies through 7 days after sotorasib dosing. This 
information will be forwarded to Amgen Global Patient Safety. Generally, infant follow -
up will be conducted up to 12 months after the birth of the child (if applicable).  
 Any termination of pregnancy will be reported to Amgen Global Patient Safety, 
regardless of fetal status (presence or absence of anomalies) or indication for procedure.  
 While pregnancy itself is not considered to be an adverse event or serious adverse event, 
any pregnancy complication or report of a congenital anomaly or developmental delay, 
fetal death, or suspected adverse reactions in the neonate will be reported as an  adverse 
event or serious adverse event. Note that an elective termination with no information on a 
fetal congenital malformation or maternal complication is generally not considered an 
adverse event, but still must be reported to the Sponsor as a pregnanc y exposure case.  
 If the outcome of the pregnancy meets a criterion for immediate classification as a serious 
adverse event (eg, female subject experiences a spontaneous abortion, stillbirth, or 
neonatal death or there is a fetal or neonatal congenital anom aly), the Investigator will 
report the event as a serious adverse event.  
 Any serious adverse event occurring as a result of a post -study pregnancy that is 
considered reasonably related to the study treatment by the Investigator will be reported 
to Amgen Gl obal Patient Safety as described in Appendix 1. While the Investigator is not 
obligated to actively seek this information in former study subjects, he or  she may learn 
of a serious adverse event through spontaneous reporting.  
 Any female subject who becomes pregnant while participating will discontinue study 
treatment (see Section  4.5 for details).  
Male Subjects with Partners Who Become Pregnant  or Were Pregnant at the Time of Enrollment  
 In the event a male subject fathers a child during treatment, and for an additional 7 days 
after sotorasib dosing,  the information will be recorded on the Pregnancy Notification 
Form. The form  (see Figure 3) must be submitted to Amgen Global Patient Safety within 
24 hours of the site’s awareness of the pregnancy. (Note: Sites are not required to provide 
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Number: 20200362  
Protocol Version 1.0, 09 February 2021  Page 54 of 67 any information on the Pregnancy Notification Form that violates the country or regions 
local privacy laws.)  
 The Investigator will attempt to obtain informed consent fo r release of pregnancy and 
infant health information directly from the pregnant female partner to obtain additional 
pregnancy information.  
 After obtaining the female partner’s informed consent for release of pregnancy and infant 
health information, the Inv estigator will collect pregnancy outcome and infant health 
information on the pregnant partner and her baby and complete the pregnancy 
questionnaires. This information will be forwarded to Amgen Global Patient Safety.  
 Generally, infant follow -up will be co nducted up to 12 months after the birth of the child 
(if applicable).  
 Any termination of the pregnancy will be reported to Amgen Global Patient Safety 
regardless of fetal status (presence or absence of anomalies) or indication for procedure.  
Collection of  Lactation Information  
 Investigator will collect lactation information on any female subject who breastfeeds 
while taking protocol -required therapies through 7 days after sotorasib dosing.  
 Information will be recorded on the Lactation Notification Form ( Figure 4) and submitted 
to Amgen Global Patient Safety within 24 hours of the Investigator’s knowledge of event.  
 Study treatment will be discontinued if the female subject breastfeeds during the study.  
 With the female subject’s informed consent for release of mother and infant health 
information, the Investigator will collect mother and infant health information and 
complete the lactation questionnaire on any female subject who breastfeeds while taking 
protocol -required therapies through 7 days after sotorasib dosing.  
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Number: 20200362  
Protocol Version 1.0, 09 February 2021  Page 55 of 67 Figure 3:  Pregnancy Notification Form  
 

Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Number: 20200362  
Protocol Version 1.0, 09 February 2021  Page 56 of 67 Figure 4:  Lactation Notification Form  
 

Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Number: 20200362  
Protocol Version 1.0, 09 February 2021  Page 57 of 67 Appendix 6: Regulatory, Ethical, and Study Oversight Considerations  
Regulatory and Ethical Considerations  
This study will be conducted in accordance with the protocol and with the following:  
 Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council f or International Organizations of Medical Sciences 
(CIOMS) International Ethical Guidelines.  
 Applicable International Council for Harmonisation (ICH) Good Clinical Practice (GCP) 
Guidelines.  
 Applicable laws and regulations.  
The protocol, protocol amendment s, Informed Consent Form (ICF), Investigator Brochure, and 
other relevant documents (eg, advertisements) must be submitted to an Institutional Review 
Board (IRB) by the Investigator and reviewed and approved by the IRB before the study is 
initiated.  
Any a mendments to the protocol will require IRB and regulatory authority (as locally required) 
approval before implementation of changes made to the study design, except for changes 
necessary to eliminate an immediate hazard to study subjects.  
The Investigator  will be responsible for the following:  
 Providing written summaries of the status of the study to the IRB annually or more 
frequently in accordance with the requirements, policies, and procedures established by 
the IRB. 
 Notifying the IRB of serious adverse  events or other significant safety findings as 
required by IRB procedures.  
 Providing oversight of the conduct of the study at the site and adherence to requirements 
of 21 Code of Federal Regulations (CFR), ICH guidelines, the IRB, European regulation 
536/2014 for clinical studies (if applicable), and all other applicable local regulations.  
Finances and Insurance  
Financing and insurance will be addressed in a separate agreement.  
Informed Consent  
An initial sample ICF will be provided for the Investigator (o r designee) to prepare the informed 
consent document to be used at his or her site. Updates to the sample ICF are to be 
communicated formally in writing from the Study Manager to the Investigator. The written ICF 
is to be prepared in the language(s) of the  potential study participant population.  
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Number: 20200362  
Protocol Version 1.0, 09 February 2021  Page 58 of 67 The Investigator or his/her delegated representative will explain to the subject, or his/her legally 
authorized representative, the aims, methods, anticipated benefits, and potential hazards of the 
study before any protocol -specific Screening procedures or any investigational product(s) is/are 
administered and answer all questions regarding the study.  
Subjects must be informed that their participation is voluntary. Subjects or their legally 
authorized representative  (defined as an individual or other body authorized under applicable law 
to consent, on behalf of a prospective subject, to the subject’s participation in the clinical study) 
will then be required to sign a statement of informed consent that meets the requ irements of 21 
CFR 50, local regulations, ICH guidelines, and the IRB or study site.  
The medical record must include a statement that written informed consent was obtained before 
the subject was enrolled in the study and the date the written consent was o btained. The 
authorized person obtaining the informed consent must also sign the ICF.  
The acquisition of informed consent and the subject’s agreement or refusal of his/her notification 
of the primary -care physician is to be documented in the subject’s medi cal records, and the ICF 
is to be signed and personally dated by the subject or a legally acceptable representative and by 
the person who conducted the informed consent discussion. Subject withdrawal of consent or 
discontinuation from study treatment and/o r procedures must also be documented in the subject’s 
medical records.  
Subjects must be re -consented to the most current version of the ICF during their participation in 
the study.  
The original signed ICF is to be retained in accordance with institutional  policy, and a copy of 
the ICF must be provided to the subject or the subject’s legally authorized representative.  
If a potential subject is illiterate or visually impaired and does not have a legally acceptable 
representative, the Investigator must provi de an impartial witness to read the ICF to the subject 
and must allow for questions. Thereafter, both the subject and the witness must sign the ICF to 
attest that informed consent was freely given and understood. (Refer to ICH GCP guideline, 
Section  4.8.9. ) 
Subject Data Prote ction 
The Investigator must ensure that the subject’s confidentiality is maintained for documents 
submitted to the Sponsor.  
Subjects will be assigned a unique identifier by the Sponsor. Any subject records or datasets that 
are transferred to the Sponsor will contain the identifier only; subject names or any information 
which would make the subject identifiable will not be trans ferred.  
On the electronic Case Report Form (eCRF) demographics page, in addition to the unique 
subject identification number, include the age at time of enrollment.  
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Number: 20200362  
Protocol Version 1.0, 09 February 2021  Page 59 of 67 For serious adverse events reported to the Sponsor, subjects are to be identified by their  unique 
subject identification number (for faxed reports, in accordance with local laws and regulations) 
and age (in accordance with local laws and regulations).  
Documents that are not submitted to the Sponsor (eg, signed ICFs) are to be kept in confidence  
by the Investigator, except as described below.  
In compliance with ICH GCP Guidelines , it is required that the Investigator and institution 
permit authorized representatives of the company, of the regulatory agency(s), and the IRB direct 
access to review the subject’s original medical records for verification of study -
related - procedures and data. Direct access includes examining, analyzing, verifying, and 
reproducing any records and reports that are important to the evaluation of the study.  
The Investiga tor is obligated to inform and obtain the consent of the subject to permit such 
individuals to have access to his/her study -related - records, including personal information.  
Disclosure  
All information provided regarding the study, as well as all informatio n collected and/or 
documented during the course of the study, will be regarded as confidential information of the 
Sponsor, Amgen Inc. The Investigator (or designee) agrees not to disclose such information in 
any way without prior written permission from th e Sponsor. The information in this document 
cannot be used for any purpose other than the evaluation or conduct of the clinical investigation 
without the prior written permission from the Sponsor.  
The Investigator must ensure that the subject’s confidentia lity is maintained for documents 
submitted to Amgen.  
Subject will be assigned a unique identifier by the Sponsor. Any subject records or datasets that 
are transferred to the Sponsor will contain the identifier only; subject names or any information 
that wo uld make the subject identifiable will not be transferred.  
On the eCRF demographics page, in addition to the unique subject identification number, include 
the age at time of enrollment.  
For serious adverse events reported to Amgen, subjects are to be identified by their unique 
subject identification number, initials (for faxed reports, in accordance with local laws and 
regulations), and age (in accordance with local laws and regulations).  
Documents that are not submitted to Amgen (eg, signed ICFs) are to be kept in confidence by the 
Investigator, except as described below.  
Data Quality Assurance  
The following data quality steps will be implemented:  
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Number: 20200362  
Protocol Version 1.0, 09 February 2021  Page 60 of 67  All relevant subject data relating to the study will be recorded on eCRFs unless directly 
transmitted to t he Sponsor or designee electronically (eg, laboratory data). The 
Investigator is responsible for verifying that data entries are accurate and correct by 
electronically signing the eCRF.  
 The Investigator must maintain accurate documentation (source data) t hat supports the 
information entered in the eCRF.  
 The Investigator must permit study -related monitoring, audits, IRB review, and 
regulatory agency inspections and provide direct access to source data documents.  
 The Sponsor or designee is responsible for the data management of this study including 
quality checking of the data. Predefined agreed risks, monitoring thresholds, quality 
tolerance thresholds, controls, and mitigation plans will be documented in a risk 
management register. Additional details of q uality checking to be performed on the data 
may be included in a Data Management Plan.  
 A Study Monitor will perform ongoing source data verification to confirm that data 
entered into the eCRF by authorized site personnel are accurate, complete, and verifi able 
from source documents; that the safety and rights of subjects are being protected; and that 
the study is being conducted in accordance with the currently approved protocol and any 
other study agreements, ICH GCP, and all applicable regulatory requirem ents. 
 Records and documents, including signed ICFs, pertaining to the conduct of this study 
must be retained by the Investigator in accordance with 21 CFR 312.62(c)  unless local 
regulations or institutional policies require a longer retention period. No re cords may be 
destroyed during the retention period without the written approval of the Sponsor. No 
records may be transferred to another location or party without written notification to the 
Sponsor.  
Investigator Documentation Responsibilities  
All individ ual, subject -specific study data will also be entered into a 21 CFR Part  11compliant 
electronic data capture (EDC) system on an eCRF in a timely fashion.  
All data generated from external sources (eg, laboratory and bioanalytical data), and transmitted 
to the Sponsor or designee electronically, will be integrated with the subject’s eCRF data in 
accordance with the Data Management Plan.  
An eCRF must be completed for each enrolled subject who undergoes any Screening procedures, 
according to the eCRF completion  instructions. The Sponsor, or Contract Research Organization 
(CRO), will review the supporting source documentation against the data entered into the eCRFs 
to verify the accuracy of the electronic data. The Investigator will ensure that corrections are 
made to the eCRFs and that data queries are resolved in a timely fashion by the study staff.  
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Number: 20200362  
Protocol Version 1.0, 09 February 2021  Page 61 of 67 The Investigator will sign and date the eCRF via the EDC system’s electronic signature 
procedure. These signatures will indicate that the Investigator reviewed and a pproved the data on 
the eCRF, data queries, and site notifications.  
Publications  
The policy for publication of data obtained during this study will be documented in the Clinical 
Study Agreement.  
 
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Number: 20200362  
Protocol Version 1.0, 09 February 2021  Page 62 of 67 Appendix 7: Hepatotoxicity: Suggested Actions and Follow -up Assessments  
Subjects with normal hepatic function at Screening who experience aspartate aminotransferase 
(AST) or alanine aminotransferase ( ALT) elevations  3 x upper limit of normal (ULN) or 
subjects with elevated values before drug exposure who have a 2 -fold increase above baseline 
values (as specified in the Guidance for Industry Drug -Induced Liver Injury: Premarketing 
Clinical Evaluation, July 2009) are t o undergo clinical assessments and a period of “close 
observation” until abnormalities return to normal or to the subject’s baseline level as described 
below.  
 
Clinical Assessments and Observation  
Assessments that are to be performed during this period inc lude:  
 Repeat AST, ALT, alkaline phosphatase, bilirubin (total and direct), and international 
normalized ratio (INR) within 24 hours  
 In cases of total bilirubin (TBL)  2 x ULN or INR  1.5, retesting of liver tests, bilirubin 
(total and direct), and INR is to be performed every 24 hours until laboratory 
abnormalities improve.  
Testing frequency of the above laboratory tests may decrease if the abnormalities stabilize.  
Initiate investigation of alternative causes for elevated AST or ALT and/or elevated TBL . The 
following are to be considered depending on the clinical situation:  
 Complete blood count with differential to assess for eosinophilia  
 Serum total immunoglobulin G, anti -nuclear antibody, anti -smooth muscle antibody, and 
liver kidney microsomal antibody -1 to assess for autoimmune hepatitis  
 Serum acetaminophen (paracetamol) levels  
 A more detailed history of:  
o Prior and/or concurrent diseases or illness  
o Exposure to environmental and/or industrial chemical agents  
o Symptoms (if applicable) including right upper quadrant pain, hypersensitivity -
type reactions, fatigue, nausea, vomiting, and fever  
o Prior and/or concurrent use of alcohol, recreational drugs, and special diets  
o Concomitant use of medications (including nonprescription medicines and herbal 
and dietary supplements), plants, and mushrooms  
 Viral serologies  
 Creatine phosphokinase, haptoglobin, lactate dehydrogenase, and peripheral blood smear  
 Appropriate liver imaging if clinically indicated  
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Number: 20200362  
Protocol Version 1.0, 09 February 2021  Page 63 of 67  Appropriate blood sampling for pharmacokinetic analysis if this has not already been 
collected  
 Hepatology consult (liver biopsy may be considered in consultation with a hepatologist).  
Follow the subject and the laboratory tests (ALT, AST, TBL, INR) until all laboratory 
abnormalities return to baseline or normal  or are considered stable by the Investigator. The 
“close observation period” is to continue for a minimum of 4  weeks after discontinuation of all 
investigational product(s) and protocol -required therapies.  
The potential drug -induced liver injury (DILI) event and additional information such as medical 
history, concomitant medications, and laboratory results must be captured in the corresponding 
electronic Case Report Form (eCRF).  
Important alternative causes for elevated AST/ALT and/or TBL values include, but are not 
limited to:  
 Hepatobiliary tract disease  
 Viral hepatitis (eg, hepatitis A/B/C/D/E, Epstein -Barr Virus, cytomegalovirus, herpes 
simplex virus, varicella, toxoplasmosis, and parvovirus)  
 Right -sided h eart failure, hypotension, or any cause of hypoxia to the liver causing 
ischemia  
 Exposure to hepatotoxic agents/drugs or hepatotoxins, including herbal and dietary 
supplements, plants, and mushrooms  
 Heritable disorders causing impaired glucuronidation (eg,  Gilbert’s syndrome, Crigler -
Najjar syndrome) and drugs that inhibit bilirubin glucuronidation (eg -, indinavir, 
atazanavir)  
 Alpha -one antitrypsin deficiency  
 Alcoholic hepatitis  
 Autoimmune hepatitis  
 Wilson’s disease and hemochromatosis  
 Nonalcoholic fatty li ver disease including steatohepatitis  
 Non-hepatic causes (eg, rhabdomylosis, hemolysis).  
Drug -induced Liver Injury Reporting and Additional Assessments  
Reporting  
To facilitate appropriate monitoring for signals of DILI, ie, cases of AST or ALT  3 x ULN and 
concurrent TBL  2 x ULN or INR  1.5 (for subjects not on anticoagulation therapy) without 
evidence of alternative cause of the elevations, require the following:  
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Number: 20200362  
Protocol Version 1.0, 09 February 2021  Page 64 of 67  The event is to be reported to the Sponsor as a serious adverse event within 24  hours of 
discovery or notification of the event (ie, before additional etiologic investigations have 
been concluded)  
 The appropriate eCRF captures information necessary to facilitate the evaluation of 
treatment -emergent liver abnormalities is to be comple ted and sent to the Sponsor.  
Other events of hepatotoxicity and potential DILI are to be reported as serious adverse events if 
they meet the criteria for a serious adverse event defined in Appendix 1. 
 
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Number: 20200362  
Protocol Version 1.0, 09 February 2021  Page 65 of 67 Appendix  8: Schedule of Assessments  
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Number: 20200362  
Protocol Version 1.0, 09 February 2021  Page 66 of 67 Schedule of Assessments  
Study Procedures  Screening  Check -
in Drug Administration  
Day -28 to  
Day -2 Day -1 Day 1  Day 2  Day 3  Day 4  Day 5  Day 6  Day 7  Day 8  
(EOS)  
Confined to the CRU   X X X X X X X X X 
Outpatient Visit  X          
Inclusion/Exclusion Criteria  X X         
Informed Consent  X          
Demographics  X          
Serology  X          
Medical History  X Xa         
Height and BMI  X          
Weight  X X        Xb 
Drug Screen  X X         
Alcohol Test   X         
Pregnancy Test (females only)c X X        Xb 
FSH (postmenopausal females only)  X          
12-lead Electrocardiogramd X X X       Xb 
Vital Signse X X X X X X X X X Xb 
Clinical Laboratory Evaluationsf X X  X    X  Xb 
eGFRg X X         
Physical Examinationh X X        Xb 
Sotorasib Dosei   X        
Sotorasib PK Blood Samplesj   X X X X X X X X 
Sotorasib Metabolite PK Blood 
Samplesk   X X X X X X X X 
Protein Bindingl   X X X X X X X X 
Adverse Event Monitoringm   X 
Serious Adverse Event Monitoringm X X 
Prior/Concomitant Medicationsn X X 
 
Abbreviations: BMI   body mass index; CRU   Clinical Research Unit; D  day; eGFR  estimated glomerular filtration rate; EOS  end of study; ET   early termination; 
FSH  follicle -stimulating hormone;  PK  pharmacokinetic.  
Protocol  CONFIDENTIAL  
Covance Study: 8454975  Amgen Protocol Number: 20200362  
Protocol Version 1.0, 09 February 2021  Page 67 of 67 a  Interim medical history only.  
b  Assessment to be performed at the End of Study (EOS) visit or early termination (ET).  
c  Performed in serum at Screening and in urine at all other times. A positive urine pregnancy test will be confirmed with a serum pregnancy test.  
d  12-lead electrocardiograms will be collected after the subject has rested in the supine position for at least 5  minutes, and will be obtained prior to the scheduled blood draws at: 
Screening; Check -in; prior to and  0.5, 2, and 4 hours postdose following administration of sotorasib on Day 1; and EOS or ET. ECG should be collected prior to any PK 
corresponding timepoints. Three sets of triplicate ECGs to be collected at baseline and 1 set of triplicate ECGs to be coll ected at any other timepoints.  
e  Vital signs measurements (supine blood pressure [BP], supine pulse rate, respiratory rate, and oral body temperature) should be carried out prior to having blood drawn. 
Screening; Check -in; prior to sotorasib administration and 1, 2, and 24 hours following sotorasib administration on Day 1; and daily thereafter. Pulse rate and BP wi ll be 
measured using the same arm for each reading after the subject has been resting in the supine position for at least 5 minutes . 
f  Clinical chemistry (fasted at least 10 hours), hematology, and urinalysis.  
g  eGFR will be calculated using the Modification of Diet in Renal Disease equation.  
h  A full physical examination at Screening and Check -in, and an a bbreviated physical exami nation at EOS/ET.  
i  Dose administration of sotorasib  will be given in the morning on Day 1 after a 10 -hour fast.  
j  Blood samples for determination of sotorasib plasma concentrations will be collected: Predose (Hour  0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 , 24, 36, 48, 72, 96, 120, 144, and 
168 hours postdose following administration of sotorasib on Day 1. The blood sample collected at 30  minutes postdose will have a sampling window of  2 minutes, samples 
collected from 1 through 3  hours postdose will have  a sampling window of  5 minutes, samples collected from 4 through 10  hours postdose will have a sampling window of 
 10 minutes, and samples collected from 12 through 168  hours postdose will have a sampling window of  20 minutes. Times of all blood samp les will be recorded to the 
nearest minute.  
k  Blood samples for determination of sotorasib metabolite plasma concentrations will be collected: Predose (Hour 0), 0.5, 1, 1. 5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, 
and 168 hours postdose follo wing administration of sotorasib on Day 1. The blood sample collected at 30 minutes postdose will have a sampling window of  2 minutes, samples 
collected from 1 through 3 hours postdose will have a sampling window of  5 minutes, samples collected from 4 through 10 hours postdose will have a sampling window of  
10 minutes, and samples collected from 12 through 168 hours postdose will have a sampling window of  20 minutes. Times of all blood samples will be recorded to the nearest 
minute.  
l  Blood samples  for determination of unbound fraction will be collected: Predose (Hour 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 , 96, 120, 144, and 168 hours postdose 
following administration of sotorasib on Day 1. The blood sample collected at 30 minutes po stdose will have a sampling window of  2 minutes, samples collected from 1 
through 3 hours postdose will have a sampling window of  5 minutes, samples collected from 4 through 10 hours postdose will have a sampling window of  10 minutes, and 
samples col lected from 12 through 168 hours postdose will have a sampling window of  20 minutes. Times of all blood samples will be recorded to the nearest minute.  
m Adverse events will be recorded from initiation of study treatment on Day 1 until EOS completion. Serious adverse events will  be recorded from the time the subject signs the 
ICF until 30 days after the last dose of study treatment or the EOS (whichever is  later).  
n Prior and concomitant medication administration will be recorded beginning at informed consent. In addition, all Investigator -approved medications taken by a subject within 
30 days or 5 half -lives (whichever is longer) prior to Check -in for over -the-counter or prescription medications, and 30  days prior to Check -in for herbal medicines (eg, St. 
John’s wort), vitamins, and supplements, will be recorded on the subject’s electronic Case Report Form.  